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I.1 Polycystic liver diseases (PLDs) 
Polycystic liver diseases (PLDs) comprise a heterogeneous group of hereditary 
genetic disorders characterized by bile duct dilatation and development of 
multiple fluid-filled biliary cysts.1 Although, it has been classically stablished that 
the minimum number of liver cysts to define PLD is 20, recent consensus reached 
by the international PLD Registry steering committee has revised this definition 
to consider hepatic disorders comprising more than 10 liver cysts.2 Some of the 
currently known risk factors for disease progression are age, female sex, 
pregnancies and use of estrogens.3,4 Patients with PLD frequently refer to 
symptoms such as abdominal distention, pain and early satiety and commonly 
display hepatic manifestations such as hepatomegaly, biliary and portal 
obstruction and cyst infection or rupture. Autosomal dominant polycystic liver 
disease (ADPLD, ~1:100,000 prevalence) is characterized by the development 
of cysts exclusively in the liver, which are the main cause of morbidity, whereas 
autosomal dominant polycystic kidney disease (ADPKD, ~1:1,000 prevalence) 
and autosomal recessive polycystic kidney disease (ARPKD, ~1:20,000 
prevalence) also present renal cystogenesis, potentially leading to hypertension 
and ultimately end-stage renal disease.2 Importantly, a recent international cross-
sectional study revealed a significant difference in the liver phenotype between 
patients with ADPLD versus ADPKD, being more frequent to observe dominant 
cysts in the patients suffering only from hepatic manifestations, and observing 
differences in the most frequently applied clinical strategies for each group.3 
Current therapies for PLDs include surgical procedures such as aspiration-
sclerotherapy, fenestration, segmental hepatic resection and trans-catheter 




liver function usually remains essentially preserved, and disease does not evolve 
to liver failure or death.2,3 For these reasons, and due to the short-term and 
modest beneficial effects of these surgical interventions together with the 
potential therapy-related complications, these procedures are only indicated in 
highly symptomatic patients in which symptoms severely affect quality of life.2 In 
addition to the mentioned surgical procedures, pharmacological treatment with 
somatostatin analogs has been applied to the treatment of PLDs.5 Somatostatin 
analogs such as octreotide or lanreotide base their therapeutic effects on their 
ability to modulate the increased levels of intracellular cyclic adenosine 
monophosphate (cAMP) found in cystic cholangiocytes that lead to increased 
proliferative activity and altered fluid secretion on these cells via PKA, EPAC and 
ERK1/2/MEK.6 These pharmacological treatments improve quality of life of 
symptomatic PLD patients by significantly reducing total liver volume (TLV) of 
these patients.5 However, the modest effect, high costs and related side effects 
of these therapies restrict their use to only particular cases.7 Therefore, providing 
the mild therapeutic outcome of current surgical and pharmacological 
approaches, liver transplantation remains as the only curative option. However, 
this last alternative turns into a very limited option due to the non-lethal nature of 
the disease and accompanied by the common issues linked to organ 
transplantation.8  
I.1.1 Genetics and molecular mechanisms of PLDs 
As mentioned above, PLDs constitute a group of genetic disorders that share 
some common features mainly in terms of clinical manifestations, being liver 
cystogenesis the central event for all PLDs. In this regard, liver cysts are thought 




and/or as a result of a somatic second hit mutations during adulthood. These 
mutations can result in loss of heterozygosity in particular disease-related genes, 
leading to deficient glycoproteins assembly and control and, ultimately, 
decreased polycystin-1 (PC-1) expression.2,9-11  
Although liver cystogenesis is a common event in all PLDs, these can differ 
in other features such as the severity of the hepatic manifestations and symptoms 
or the presence or absence of extrahepatic manifestations. Importantly, these 
differences seem to be very closely related to the genetic background triggering 
disease.12,13 In this regard, exhaustive research in the last decades, and in 
particular increasing efforts made in the last 20 years have allowed a better 
understanding of the pathophysiology and the molecular mechanisms involved in 
the development and progression of PLDs.  
 
 
Figure I1. Number of publications between years 1990 and 2018 reported by Web of Science for 
the search topic ‘’polycystic liver disease’’. (Accessed database at 





To date germline mutations in nine different genes have been described to be 
related to development and progression of PLDs (Table I1).9,14 
 
Table I1. Genes for which somatic mutations have been described to be related in development 
and progression of PLDs. Modified from refs. 9,14 
 
Mutations on these genes produce several functional alterations in 
cholangiocytes that are directly associated to increased levels of cAMP and 
decreased intracellular calcium (iCa2+) concentration.1  These alterations include 
hyperproliferation,6,15 hypersecretion,16 increased matrix metalloproteolytic 
activity,17 changes in  microRNAs expression patterns18 and morphological and 
functional alterations of the primary cilium,19 and are the responsible for the 
pathobiology of PLDs. Thus, the increasing knowledge on the pathophysiology of 
PLDs is proposing new potential targets for therapy. In particular, due to its 
hepatoprotective and choleretic properties, together with its strong capacity to 
regulate iCa2+, ursodeoxycholic acid (UDCA) has been tested as a potential 




with this endogenous bile acid (BA) has been shown to produce significant 
inhibition of hepatobiliary cystogenesis, providing substantial beneficial effects 
both, in experimental models of PLD (PCK rats) and a subgroup of patients with 
ADPKD (Phase II clinical trial).15,20 On the other hand, histone deacetylase 6 
(HDAC6) has been shown to be upregulated in cystic cholangiocytes.21 This 
enzyme catalyzes deacetylation of α-tubulin, an important component of 
cholangiocyte primary cilium, and its enzymatic activity has been directly linked 
to ciliary disassembly.22 Therefore, and providing the importance of primary cilium 
in cholangiocyte pathobiology, pharmacological HDAC6 selective inhibition of 
has also been tested as a potential therapeutic strategy for the treatment of 
PLDs.21,23 
 
I.2 Ursodeoxycholic acid (UDCA) 
BAs are synthesized in the liver by hydroxylation and modification of cholesterol 
to yield a number of different amphipathic chemical entities that contribute to the 
emulsification, absorption and transport of nutrients, fats and vitamins from the 
gastrointestinal tract.24 The multistep process of BA synthesis within hepatocytes 
involves participation of different enzymes located to the endoplasmic reticulum, 
mitochondria, cytosol and peroxisomes.25  
UDCA is a choleretic and hepatoprotective BA that possesses antioxidant, 
anti-inflammatory and cytoprotective properties.26 This endogenous BA has been 
extensively applied in the clinic for the treatment of hepatobiliary cholestatic 
disorders. Nowadays, UDCA is the first-line pharmacological treatment in 




Importantly, unlike the major portion of bile acids within human bile, UDCA is 
synthetized in the gastrointestinal tract by bacterial metabolism.28  
From a chemical perspective, UDCA is a C24 BA with a cyclopentane-
perhydro[a]phenanthrene scaffold carrying 3α and 7β hydroxylations and a C4 
side chain methylated in C-20 and ended on a carboxylic acid (Figure I2C).  
 
Figure I2. Fully optimized and strain energies (OPLS_2005 force field29 in water) of (A) (5R)- 
cyclopentaneperhydro[a]phenanthrene (cholestane scaffold), (B) (5S)-cyclopentane 
perhydro[a]phenanthrene (coprostane scaffold), and (C) ursodeoxycholic acid. The significant 
axial and equatorial positions are highlighted in red and green, respectively. The ten most stable 
conformations in UDCA within 3 kJ/mol are also represented in (C). 
 
It is important to note that the structure of the steroidic scaffold of 




junction of rings A and B. If these two cyclohexane rings are fused in trans (Figure 
I2A), the C4 carbon atom occupies an equatorial position thus presenting an all-
trans geometry for the whole tetracyclic system. This skeleton can be found in 
the cholestane series of steroids. When the (5,10) fusion results in a cis 
configuration for the A-B rings, the chair conformation of the 
perhydrophenantrene moiety generates an axial disposition for the resulting 
structure (Figure I2B). This gives rise to the coprostane series of steroids, which 
is thermodynamically ca. 10 kJ/mol less stable than the cholestane series (see 
Figure I2A and B). As far as the UDCA structure is concerned, inspection of its 
stereochemistry shows that it belongs to the coprostane series. In addition, the 
two hydroxy groups at C-3 and C-7 occupy axial and equatorial positions, 
respectively (Figure I2C). This results in thermodynamically less stable 
geometries. Importantly, although the coprostane scaffold is quite rigid, the 
pentanoic acid chain is flexible (Figure I2C). This allows to hypothesize that 
UDCA conjugates will combine the rigidity of the coprostane polycyclic moiety 
with the conformational flexibility of the lateral chain, thus resulting in a good 
trade-off between preorganization and adaptative character, as we will see later. 
Similar to the rest of BAs, UDCA displays poor water solubility in its 
protonated form. Actually, it precipitates in water at a pH value of 7.0-7.1 and 
shows a solubility in this solvent of 53 µM.30 Its pKa value at 20ºC, 10 mM in water, 
is 5.24.30 However, the presence of the two hydroxy groups as well as the β 
position of the C-7 hydroxylation provide UDCA with higher hydrophilicity when 
compared to mono-hydroxylated BAs like lithocholic acid (LCA) or 7α-
hydroxylated BAs like cholic acid (CA) or chenodeoxycholic acid (CDCA).31,32 




unconjugated protonated form, UDCA is solubilized in the proximal jejunum by 
formation of mixed micelles with endogenous bile acids, and is mostly absorbed 
in the small intestine by dissolution-limited passive nonionic diffusion.33 
Therefore, UDCA absorption is directly influenced by endogenous BA 
concentration in the intestinal lumen, being enhanced during meals and 
substantially decreased in cholestatic patients.34 After absorption, UDCA reaches 
the liver through the portal circulation where is actively uptaken by hepatocytes 
by means of specific bile acid transporters sodium-taurocholate cotransporting 
polypeptide (NTCP) and organic anion transporting polypeptides (OATPs).31,35 
Once inside hepatocytes, UDCA is effectively amidated to its glycine 
(preferentially in humans) and taurine (preferentially in rats) conjugates and 
actively secreted into bile.33 After reaching the gastrointestinal tract, UDCA 
conjugates are reabsorbed by enterocytes in the distant ileum through the apical 
sodium-dependent bile salt transporter (ASBT) and are re-circularized into the 
liver accomplishing an effective enterohepatic circulation.34 Finally, the portion of 
UDCA and its conjugates that is not absorbed is metabolized by colon microbiota 
into LCA that is further eliminated via feces.34 This restricted biodistribution circuit 
is a clear advantage for the therapeutic use of UDCA and its derivatives in 
hepatobiliary disorders.  
At the cellular level, UDCA and its conjugates are potent signaling 
molecules able to stimulate iCa2+ levels.36,37 Importantly, they have been proven 
to exert significant cytoprotective effect against cytotoxic BAs.26 UDCA and/or its 
conjugates are able to modulate a number of important cellular processes carried 




secretion; transcriptional, post-transcriptional and functional regulation of specific 
transporters; and finally cell survival.27,34  
As mentioned before, one of the central events in hepatic cystogenesis is 
the decreased iCa2+ levels of cystic cholangiocytes that lead to hyperproliferation 
and impaired secretory activity of these cells. Therefore, providing the capacity 
of UDCA to rise the iCa2+ concentration, as well as its safety and tolerability, 
Banales JM and co-workers proposed the administration of UDCA as a potential 
pharmacological strategy for the treatment of PLDs.15 In this study, Munoz-
Garrido P. et al demonstrated that chronic oral administration to PCK rats (animal 
model of ARPKD) with UDCA reduced hepatic cystogenesis and fibrosis as well 
as improved their symptomatology (motor behavior). Furthermore, the analysis 
of the BA profile of PCK rats revealed that UDCA administration decreased the 
intrahepatic accumulation of toxic BAs, which promote cystogenesis. Based on 
these results, an International Multicenter Phase II Clinical Trial was conducted 
to test the potential therapeutic value of UDCA for the treatment of patients with 
PLD.20 In highly symptomatic patients, administration of UDCA for 6 months did 
not modified the total liver volume but significantly reduced the liver cystic volume 
of patients with ADPKD. On the other hand, this effect was not observed in 
patients with ADPLD. Moreover, UDCA improved the symptomatology and 
reduced the levels of markers of cholestasis in patients with PLD, and showed 






I.3 Histone deacetylases (HDACs) 
Histone deacetylases (HDACs) are a family of hydrolase enzymes that catalyze 
deacetylation of lysine residues located within different histone and non-histone 
protein substrates (Scheme I1). These enzymes are essential for the correct 
functioning of a wide number of cellular processes, since they are key modulators 
of both gene expression and protein activity.38,39  
 
Scheme I1. N-deacetylation of an acetyl lysine residue of a histone catalyzed by HDACs. 
 
Current consensus classification of HDAC family includes a total number 
of four subclasses (Figure I3). Class III is the most largely differing from the 
others, being composed by a particular type of HDACs called sirtuins (SIRT1-7) 
that involve participation of NAD+ as a cofactor to carry out catalytic activity. On 
the other hand, the so-called ``classical HDACs´´ gather into classes I, II (divided 
into IIa and IIb), and IV. Class I comprises HDAC1-3 and 8, while class II is 
subsequently subdivided into IIa, composed of HDAC4, 5, 7 and 9 and IIb that 






Figure I3. Molecular phylogenetic classification by the Maximum Likelihood method. The 
evolutionary history was inferred by using the Maximum Likelihood method based on the JTT 
matrix-based model. Calculations were performed with MEGA6 software.41 
 
Members of classes I, IIa, IIb and IV contain a Zn(II) cation in their active 
sites to participate in the catalytic activity. These enzymes show distinct 
preferential cellular localizations (Table I2), and participate in the modulation of a 
wide range of physiological processes, such as differentiation, cell cycle 
regulation, modulation of cytoskeletal dynamics, metabolic processes, autophagy 
and apoptosis among many others.42-44 
Table I2. Class arrangement and subcellular localization of Zn(II)-dependent HDACs. Modified 




Members of the HDAC family considerably differ in sequence length, from 
the 347 aminoacid sequence of HDAC11 (Uniprot id: Q96DB2) to the 1,215 
residues contained in HDAC6 (Uniprot id: Q9UBN7). However, in spite of the 
significant differences in terms of substrate preference and subsequent biological 
function, all members of the mentioned subclasses share highly conserved 
catalytic domains (CDs) (Figure I4).  
 
 
Figure I4. Schematic representation of the domains organization and amino acid sequence length 
of HDACs 1-11. In HDAC6, CD1 and CD2 refer to catalytic domains 1 and 2 respectively. Modified 






I.3.1 HDACs in pathobiology 
Expression and/or activity of different HDACs has been found impaired in a 
considerable number of pathological situations, and therefore have been 
proposed as potential therapeutic targets for the treatment these.43,47-50 In this 
regard, the particular architectural features of the active sites of HDACs make 
them highly druggable targets. However, the high degree of evolutionary 
conservation in their CDs has become a limitation to achieve isoform selective 
inhibition. In this regard, although a considerable number of clinical trials has 
been carried out with several HDAC inhibitors (HDACis), to date only five of these 
drugs have obtained FDA approval for clinical applications. Moreover, their use 
has been restricted to very particular indications, mainly hematological 
malignancies (Table I3).51 
Valproic acid (VPA) is a weak HDACi that can be considered the exception 
to the rule since it has been extensively used for years in the treatment of epilepsy 
and has also been involved in a high number of clinical trials.52 More recently, 
four new inhibitors have been approved by FDA for different indications: 
Vorinostat,53  also known as SAHA, and Romidepsin54 for the treatment  of 
cutaneous T-cell lymphoma, Belinostat55 for the treatment of peripheral T-cell 
lymphoma, and finally Panobinostat56 for the treatment of multiple myeloma 
(Table I3). Interestingly, three of these four drugs are hydroxamic acids, and only 

















I.3.2 Inside HDACs catalytic domain: general model of HDAC inhibition 
As mentioned above, all Zn(II)-dependent HDAC isoforms present highly 
conserved CDs to carry out deacetylation catalysis. Several reaction 
mechanisms have been proposed to explain HDAC hydrolase activity.58,59 Among 
them, the first and most broadly accepted reaction mechanism was proposed in 
1999 by Finnin et al. (Scheme I2).60  
 
 
Scheme I2. (A) Three-dimensional distribution of the main residues responsible of the catalytic 
activity within human HDAC1 active site. (B) Reaction mechanism proposed for HDAC-catalyzed 





This consists of a two-step mechanism that starts with the coordination of a water 
molecule and the carboxy group of the acetyl lysine to the Zn(II) cation. This 
allows the nucleophilic attack of the water molecule to the carboxamide group of 
the acetyl lysine to form an unstable tetrahedral intermediate. The instability of 
this fleeting species induces the formation of the carboxylate anion and the 
protonated amino group via hydrogen donation of a histidine residue to the lysine 
amino group. (Scheme I2). 
HDAC CDs can be schematically described as an ensemble of shallowed 
external cavities connected through a hydrophobic channel with a Zn(II) 
containing catalytic site (Figure I5A). In addition, some HDAC isoforms, but not 
all, contain what is called the acetate release channel (Figure I5A).61 
 
 
Figure I5. (A) Schematic representation of the architecture of HDACs deacetylation domains. 1: 
external cavities; 2: hydrophobic channel; 3: acetate release channel. (B) General 






According to the structural features of HDACs, a general pharmacophore 
model has been extensively applied in our group for the design and development 
of HDACis.62,63 This model divides the entire inhibitor structure into three main 
substructures. These consist of: i) an external van der Waals cap (denoted as a 
in Figure I5B), that would ideally accommodate and interact with amino acids 
present on the external cavities, ii) a hydrophobic linker (denoted as b in Figure 
I5B) of adequate length that would enter and cross the hydrophobic channel, and 
finally iii) a Zn (II) chelating agent (denoted as c in Figure I5B) that would strongly 
interact with the Zn (II) cation present in the active site (Figure I5).62 Importantly, 
although this model is applicable to the majority of HDACis developed to date, it 
cannot be taken as a rule of thumb, since there is a non-negligible number of 
HDACis that do not match this general model.64-66 
 
I.3.4 HDACis: from the pharmacophore model to their particular structures 
Many different strategies have been developed for the design of effective 
HDACis. A wide number of chemical entities has been designed and structurally 
refined in the search for HDACis with optimized activity and selectivity. The most 
extensively studied inhibitor types are described below. 
 
I.3.4.a Hydroxamic acids 
Hydroxamic acids are usually obtained by reaction of an activated carboxy group 






Scheme I3. General equation describing the synthesis of hydroxamic acids by reaction of an 
activated acyl group with the hydroxylamine. Modified from ref. 68 
 
Hydroxamic derivatives are weak acids with a strong chelating capacity to 
form very stable mono or bidentate complexes with different metal ions, being 
this ability the main responsible for their pharmacological properties (Figure 
I6).70,71  
 
Figure I6. (A) Usual coordination mode of hydroxamic acids to Zn(II) catalytic centers. (B) X-ray 
structure of hydroxamic acid trichostatin bound to  HDAC homolog from Aquifex aeolicus (PDB 
code: 1C3R). 
 
Different hydroxamic acid derivatives have been extensively shown to be 
effective inhibitors of a wide number of Zinc metalloproteases.72 In accordance, 
hydroxamic acids are most probably the type of HDACis with the largest number 
of examples developed to date. Interestingly, Trichostatin A, a potent HDAC 
hydroxamic pan-inhibitor is produced in nature by Streptomyces hygroscopicus.73 
In particular, three of the five FDA approved HDACis (i.e., Vorinostat, Belinostat 




compounds belonging to this group are currently involved in different phases of 
clinical trials (Table I3), emphasizing the considerable potential of this type of 
chemical entities for the future development of new HDACis.  
 
I.3.4.b Benzamides 
Benzamide HDACis can be obtained by amide bond formation between a 
carboxylic acid and an ortophenylenediamine eventually substituted in different 
positions of the aromatic ring. This type of reaction requires the activation of the 
carbonyl carbon by introduction of an electron withdrawing group provided by a 
peptide coupling reagent in order to allow the attack of the amino group (Scheme 
I4).74 
 
Scheme I4. Schematic representation of benzamide formation mechanism using 2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) as peptide coupling 




Benzamide groups exhibit good Zn(II) binding capacity what provides them with 
their HDAC inhibitory potential (Figure I7) 
 
 
Figure I7. (A) Usual coordination mode of ortho-aminobenzamides to Zn(II) catalytic centers. (B) 
X-ray structure of N-(4-aminobiphenyl-3-yl)benzamide bound to  human HDAC2 (PDB code: 
3MAX). 
 
However, experiments performed in purified HDACs have shown that 
benzamides show considerably slower association and dissociation kinetic rates 
than those of hydroxamic acids.76 Importantly, this type of HDACis display a high 
degree of selectivity mainly towards class I HDACs (Table I3).77,78 In this regard, 
the increased bulkiness and rigidity of benzamides compared to hydroxamic 
acids may be determinant for the particular selectivity of these compounds. 
Several examples of benzamide HDACis have been involved in clinical trials such 
as Entinostat, 79 Tacedinaline80 and Mocetinostat81,82 among others. However, to 






I.3.4.c Short chain fatty acids (SCFAs) 
Short chain fatty acids (SCFAs) such as Valproic and Butyric acids are HDACis 
of relatively simple chemical structure. This type of inhibitors usually exert HDAC 
inhibition in the micromolar range, being substantially less potent than members 
belonging to other inhibitor types. In this regard, although Valproic acid has 
proved to be effective for the treatment of epilepsy, the use of this type of 
inhibitors for other pathological conditions such as cancer is strongly limited by 
their low potency and selectivity and their fast metabolic elimination.83 A 
fascinating feature of this type of inhibitors is that they are continuously being 
produced in the human organism by metabolic processes carried out by gut 
microbiota.84 In this regard, there is an increasing number of works describing the 
important role of SCFAs as endogenous epigenetic modulators of different 
physiological and pathophysiological processes, mainly related to the immune 
system.85-88 Therefore, it cannot be discarded that the link between the gut 
microbiome and the development of other disorders, in which epigenetic 
impairments have been observed, could be somehow related to the HDAC 
inhibitory capacity of SCFAs. 
 
I.3.4.d Macrocycles 
Macrocyclic HDACis are the type of inhibitors carrying the most complex van der 
Waals cap moieties. Depending on their chemical nature, these can be classified 
into peptide macrocycles including cyclic tetrapeptides and cyclic depsipeptides, 
peptide mimetic macrocycles, and non-peptide macrocycles.89 Importantly, the 




confers them very interesting properties in terms of isoform selectivity.90 From a 
classical HDACi perspective, the main reason for this would be that the largest 
degree of sequence disparity between the CDs of the different HDAC isoforms is 
found in the external cavities surrounding the hydrophobic channels,91 being 
excellent targets for selective inhibition. Interestingly, HDACs are often found 
forming complexes with other proteins to carry out specific activities. For this 
reason, novel strategies based on the use of macrocycles to disrupt HDAC-
multiprotein complexes rather than focusing in Zn(II) chelation into the active site 
have been recently proposed to finer tune HDAC inhibitory selectivity.92,93  
Focusing on peptide macrocycles, a considerable number of these 
compounds possessing HDAC inhibitory capacity has been found to be naturally 
produced by different microbial sources.94 An striking example of these peptide 
macrocyclic HDACis is Romidepsin, also known as FK228, which is a cyclic 
depsipeptide produced by Chromobacterium violaceum,95  being the only 
macrocyclic HDACi approved by FDA for a particular clinical indication (Table I3), 
in this case cutaneous T-cell lymphoma.96 Interestingly, Romidepsin does not 
exert any HDAC inhibitory activity by itself but rather consists of a stable prodrug 
that acquires HDAC inhibitory capacity upon in vivo disulfide bond reduction to 
form two thiol groups, being one of them able to act as an effective Zn(II) chelating 
group to drive HDAC inhibition.97 
 
I.3.4.e Hybrid HDACis 
An interesting concept that has attracted great interest in the field of cancer 




The design of this type of drugs is usually based on the combination of two 
pharmacophore models for different targets into the same chemical structure to 
provide the drug with multi-targeting capacities.98 The use of hybrid drugs has 
been proposed to be an effective strategy to overcome the compensatory 
mechanisms often displayed by tumor cells to develop resistance to 
monotherapy.89 Furthermore, the forced concomitant presence of the two distinct 
pharmacologically active entities into the same cell could be the key advantage 
to prevail the use of hybrid drugs over conventional combinatorial 
pharmacological treatments.99 A proposed strategy for the design of new hybrid 
drugs has been the covalent combination of two pharmacologically active 
moieties into what has been called a mutual pro-drug by means of an inert linker 
that would ideally be enzymatically cleaved in the target cell or tissue to exert 
additive or synergistic effects.100,101 Hybrid strategies have been also proposed 
for delivering classical chemotherapy with improved targeting selectivity and 
reduced toxicity. A striking example of this strategy have been the development 
Bamet compounds that consist of the combination of a transition metal containing 
molecule such as cisplatin with different bile acids resulting in excellent antitumor 
activity with significantly improved liver vectorization and subsequently reduced 
systemic side effect events.102-104 
In a slightly different way, the importance of the cap moiety for dictating 
inhibitory activity and selectivity of HDACis makes these excellent candidates for 
the development of new hybrid drugs. In this regard, the van der Waals cap of 
HDACis can be extensively modified to fulfil the requirements of a wide number 
of pharmacophore models, while directly influencing both HDACi activity and 




develop hybrid drugs in which both substructures could cooperate to optimize 
HDACi performance and subsequently provide additional pharmacological 
effects. 
Some interesting examples have been developed by combining the 
classical pharmacophore model for HDAC inhibition with other components able 
to modulate activity of distinct cancer-related targets such as protein kinases, 
nuclear receptors, and epigenetic effectors, among others.98,100 
 
I.3.5 HDAC6 
HDAC6 is a member of the Zn(II)-dependent family of HDACs that possesses 
some interesting structural particularities (Figure I4). Its amino acid sequence 
containing 1,215 residues is the longest of the HDAC family. Unlike the other 
HDAC isoforms, HDAC6 incorporates two tandem Zn(II)-containing CDs (CD1 
and CD2). This enzyme also possesses a C-terminal Zn finger ubiquitin binding 
domain (BUZ) that allows it to bind ubiquitinated proteins.105 This particular motif 
converts HDAC6 in an important effector for aggresome formation and 
autophagosome maturation, two events involved in the clearance of misfolded 
proteins that are essential for the maintenance of cell homeostasis.106-110 Another 
interesting feature that distinguishes HDAC6 from most of the other HDAC 
isoforms is its preferential localization to the cell cytoplasm that is promoted by 
the presence of a N-terminal nuclear export signal (NES) and a serine-glutamate 
tetradecapeptide also known as SE14 motif that acts as cytoplasmic retention 
signal.111,112 In addition, HDAC6 exerts its deacetylation activity on several 




cortactin, or β-catenin.113-116 For many years, the individual catalytic role of each 
CD within HDAC6 has remained a matter of controversy.117 However, recently 
published directed mutagenesis experiments combined with structural 
crystallographic and enzymatic activity analysis provided important information 
for the understanding of the biological significance of both HDAC6 CDs.118,119 
These studies revealed that despite the high degree of structural homology 
between both CDs, they possess some differences that significantly affect their 
respective catalytic activities. In this regard, although both CDs are catalytically 
active, CD1 seems to display very stringent substrate selectivity towards C-
terminal acetylated lysines, while CD2 exhibits much broader substrate tolerance, 
being the responsible for HDAC6-mediated α-tubulin deacetylation, either in its 
monomeric form or as part of microtubule polymers.120 
HDAC6 is involved in many important cellular processes, such as cell 
proliferation, ciliary disassembly, cell motility and migration, cytoskeletal 
dynamics, misfolded protein degradation and control, and even innate immunity-
driven pathogen sensing and destruction.22,121-126 For this reason it is not 
surprising that impaired HDAC6 expression and/or activity have been directly 
linked to a large number of pathological situations. Therefore, given its high 
druggability potential, HDAC6 inhibition has been proposed as a promising 
therapeutic target for the treatment of several pathologies.127 In this regard, 
exhaustive efforts during the last decades have yielded promising drug 
candidates for selective HDAC6 inhibition, being Tubastatin A, Tubacin, ACY-
1215 and QTX125 probably the ones most extensively applied for further 




Nowadays, HDAC6 is considered a hot-spot target for several 
neurodegenerative and tumor-related disorders.117,130,132-136 Furthermore, since 
HDAC6 plays a central role in microtubule destabilization and ciliary disassembly, 
it is attracting a significant degree of interest as a potential target for the treatment 
of several types of so-called ciliopathies.22,137 Within this context, development of 
new HDAC6is with strong and selective inhibitory capacity, additional therapeutic 
properties, improved pharmacokinetics, and optimal tissue selectivity are 
warranted and may have significant therapeutic implications. 
 








I.4 The primary cilium 
The primary cilium is a microtubule-based organelle present in most mammalian 
cell types, and is commonly found as a thin projection of the apical membrane of 
different epithelial cells, including cholangoicytes.138-140 Although for long time 
this organelle was considered to be simply vestigial, in the last two decades, 
advances in the understanding of primary cilium biology have granted it as an 
important sensory organelle with a critical role in microenviromental sensing and 
cell cycle regulation.139,141-143 
The structural scaffold of primary cilium consists of an axoneme formed by 
nine microtubule doublets that protrude from a basal body and is covered by a 
specialized domain extension of the plasma membrane called ciliary membrane 
(Figure I9A).144  The primary cilium axoneme (9+0) differs from the one present 
in motile cilia (9+2) in the absence of central microtubules as well as other key 
proteins usually involved in cilia motility (Figure I9B).144 
Tubulin within the axonemal microtubules can be subjected to several post-
translational modifications directly affecting microtubule dynamics, organization, 
and interaction with other cellular components.146  Importantly, long-lived ciliary 
axonemal microtubules are highly enriched in α-tubulin acetylated in lysine 40 
(K40), and therefore a causal relation between tubulin acetylation and cilia 
stabilization has been largely suggested.147-149 Interestingly, α-tubulin K40 
acetylation by tubulin acetyl transferase enzymes is enhanced in microtubules 
over unpolimerized tubulin.148,150 This finding seems to indicate that tubulin 
acetylation within microtubules is an important post-polymerization hallmark of 




HDAC6 overexpression and/or increased activity has been tightly linked to cilia 
shortening and resorption in a large number of experimental models. Most 
importantly, pharmacological inhibition of its deacetylase activity has been shown 
to result in significant improvement in the number of ciliated cells, cilia structure 
and biological function.151-157 
 
Figure I9. (A) Schematic representation of the scaffolding structure of primary cilium. (B) 
Schematic representation of a cross-section of the axoneme of a primary cilium and a motile 
cilium. (9+0) refers to the radial disposition of the nine microtubule doublets within primary cilium 
axoneme. (9+2) refers to the radial disposition of the nine microtubule doublets and the presence 
of an additional pair of central microtubules in motile cilium axoneme. In the motile cilium, yellow 







I.4.1 The primary cilium in cholangiocytes 
Cholangiocytes are the epithelial cells lining the intra and extrahepatic bile 
ducts.158 In addition to other important physiological implications, these cells carry 
out highly specialized transport functions that are essential to modulate bile 
composition.159 In healthy biliary epithelia, primary cilia extend from the apical 
plasma membranes of cholangiocytes into the ductal lumen. This sort of ‘’cellular 
antenna’’ or ‘’mechano-osmo-chemical’’ sensor is able to detect changes in bile 
flow, bile composition and biliary osmolality and trigger distinct intracellular 
signals in response to these.160,161 In this regard, it has been demonstrated that 
cholangiocyte primary cilium is able to detect hypotonicity through the Ca2+-
permeable channel TRPV4, what induces an increase in [iCa2+], subsequent 
release of ATP and finally bicarbonate secretion.162 This finding highlights the 
importance of cholangiocyte primary cilia for the regulation of the fine-tuned 
cholangiocyte driven mechanism of bile fluidization and alkalization through 
HCO3- secretion.163,164 Interestingly, it has also been shown that primary cilia of 
cholangiocytes are able to interact and respond to biliary exosomes, clearly 
suggesting a potential implication of this organelle in distant cell communication 
events.165 Finally, the primary cilium is a pivotal regulator of cell cycle and polarity, 
depicting the critical importance of this organelle for normal cholangiocyte 
biology.11 
 
I.4.2 HDAC6 and primary cilium in cholangiopathies and polycystic diseases 
Experimental evidences have largely demonstrated that primary cilium is a 




surprising that structural and/or functional abnormalities in this organelle have 
been found in several cholangiopathies, being particularly relevant in PLDs and 
cholangiocarcinoma (CCA).166 
 
I.4.2.a Polycystic diseases 
A previous report by Gradilone and collaborators demonstrated that HDAC6 is 
overexpressed in cystic cholangiocytes in vitro and in vivo.21 This finding 
encouraged authors to analyze the therapeutic potential of Tubastatin-A, 
Tubacin, and ACY-1215, three well-known selective HDAC6is for the treatment 
of PLDs. Interestingly, they found that pharmacological HDAC6 inhibition resulted 
in decreased cystic cholangiocyte proliferation accompanied by a significant 
decrease in β-catenin expression, and important activator of transcription and cell 
cycle progression through Wnt signaling.167 Importantly, translation of this 
treatment into PCK rats, an animal model of PLDs, resulted in significant 
decrease of hepatorenal cystogenesis upon 4-week treatment (daily 
intraperitoneal treatment with 30 mg/kg day of ACY-1215).21  
Since somatostatin analogues are currently the only available 
pharmacological treatment for PLDs, Pisarello and collaborators explored a 
combinatorial approach based in co-administration of a somatostatin analogue 
(i.e. Pasireotide) together with a HDAC pan inhibitor (i.e., Panabinostat) or 
selective HDAC6is (i.e., ACY-1215, ACY-738, and ACY-241). Then, these 
authors compared the therapeutic potential of the combined treatment versus 
individual administration of each drug alone to reduce hepatorenal 




1215 and Pasireotide resulted in the highest levels of cAMP reduction and 
antiproliferative effect in cholangiocytes. Interestingly, the HDAC6 selective 
inhibitor ACY-1215 inhibited hepatorenal cystogenesis significantly more than 
HDAC pan-inhibitor Panabinostat. Finally, it was found that combination of ACY-
1215 and Pasireotide was the treatment that provided the best therapeutic 
outcome in terms of cilia length restoration and hepatorenal cystogenesis 
inhibition. Therefore, these two studies highlight the promising therapeutic 
potential of HDAC6is for the treatment of PLDs, and also suggest that combining 
HDAC6is with chemical entities modulating other important disease-related 
targets, such as cAMP or iCa2+, could be an effective strategy to circumvent 
virtual compensatory mechanisms leading to monotherapy failure. 
In parallel to these studies, Li  et al. reported the cytoplasmic accumulation 
of HDAC6 in cyst-lining epithelial cells in human ADPKD renal tissue and kidneys 
of an animal model of PKD.168 In accordance, Cebotaru et al. and Yanda et al. 
reported significant inhibition of renal cystogenesis and improved renal function 
in Pkd1fl/fl;Pax8rtTA;TetO-cre mice (induced animal model of PKD) upon treatment 
with Tubacin and ACY-1215, two selective HDAC6is.169-171 These studies 
reinforce the conclusions reported by Gradilone et al. and Pisarello et al. in the 
PCK rats. Importantly, taking all these studies together, HDAC6 emerges as a 
potential molecular bridge between PLDs and PKDs, two pathologies that often 
arise in parallel. Therefore, these findings point selective HDAC6is as promising 
therapeutic tools that, in combination with modulators of other polycystic disease-
related pathways, could settle the basis for next generation pharmacological 





I.4.2.b Cholangiocarcinoma (CCA) 
Regarding CCA, another study reported by Gradilone and collaborators depicted 
the strong relation between cholangiocyte primary cilium impairment and CCA 
pathobiology.172 In this study, these authors demonstrated that the primary cilia 
were impaired or absent in CCA cells in vitro and in vivo, and experimentally-
induced deciliation of normal cholangiocytes resulted in acquisition of a pro-
malignant phenotype through activation of Hedhehog and MAPK signaling 
pathways. Importantly, cilia abnormalities appeared to be directly related to 
HDAC6 overexpression in CCA. In this regard, molecular downregulation and 
pharmacological inhibition of HDAC6 restored primary cilia in CCA cells leading 
to a significant reduction of cell proliferation, anchorage-independent growth and 
invasion, and ultimately in vivo tumor growth. Inspired by these results, interesting 
findings have been recently reported about the regulatory functions of primary 
cilium chemosensation in CCA migration, invasion and tumor growth; the 
importance of miR-433 and miR-22 for HDAC6-induced cilia impairment in CCA 
or even the potential implication of cilia loss in the development of primary 
sclerosing cholangitis (PSC)-derived CCA.173-175 Moreover, the importance of the 
ciliary-associated localization of the bile acid receptor TGR5 for cholangiocyte 
pathobiology, together with the increasing evidence of the critical role of TGR5 
overexpression in CCA development and progression, may provide important 



































Pharmacological approaches based on the administration of either UDCA or 
HDAC6is have provided very promising, but still partial, results for the treatment 
of PLDs have been obtained so far.15,20,21,23 For this reason we hypothesized that 
new chemical entities combining UDCA and HDAC6i activity into the same 
chemical structure could provide added and/or synergistic value for the treatment 
of PLDs. In this regard, it is known that pre-organized macrocyclic systems can 
exhibit high non-covalent binding constants with the external cavities close to the 
rim that connects the active sites of HDACs with the surface of these 
enzymes.91,178,179 For this reason, and considering the polycyclic nature of the 
UDCA scaffold, we rationalized that this endogenous BA could be a suitable 
conformationally restricted analogue to these macrocyclic systems, and therefore 
an excellent structural element for the development of high performance 
HDAC6is. Furthermore, we reasoned that some of the inherent hepatotropic 
properties of UDCA could be transferred to these new HDAC6is, thus improving 
liver targeting and entero-hepatic re-circularization, as well as active transport 
into cystic cholangiocytes. Importantly, metabolic cleavage of the amide bond by 
intestinal microbiota is not expected to generate potentially toxic metabolites but 
rather could result in the release of therapeutic concentrations of free UDCA that 













Figure H1. Graphical representation of the general hypothesis in this dissertation. 
 
 




In order to evaluate the described hypothesis, the following objectives were 
proposed: 
i. Design, chemical synthesis and characterization of new synthetic 
conjugates of UDCA. 
 
ii. Computational prediction of the binding affinities of UDCA-HDAC6is for 
HDAC6 CD1 and C2. 
 
iii. In vitro evaluation of the HDAC inhibitory activity and selectivity of UDCA-
HDAC6is on individual HDACs and cystic cholangiocytes. 
 
iv. Computational and experimental study of the chemical and structural 
factors that drive HDAC6 activity and selectivity in UDCA-HDAC6is. 
 
v. Evidence-based selection of the UDCA-HDAC6i with higher translational 
potential for further in vivo and in vitro studies. 
 
vi. In vivo evaluation of the therapeutic potential of UDCA-HDAC6is for the 
treatment of PLDs.  
 



































R.1 Design and chemical synthesis of new synthetic conjugates of UDCA 
We applied to the X-ray structure of the CD2 of human HDAC6 (PDB code: 
5EDU)119 a HDAC inhibition model previously described by our group62 (Figure 
R1). According to this model, HDAC6 active sites can be schematically described 
as an ensemble of external shallow cavities connected through a hydrophobic 
channel with a Zn(II) cation containing catalytic site. Following this general model, 
we designed a family of new synthetic UDCA conjugates (i.e., UDCA-HDAC6i #1-
10), in which the tetracyclic skeleton of UDCA acted as the external van der 
Waals cap of the inhibitor, followed by a number of different hydrophobic spacers 
ended on a Zn(II) chelating group (Figure R1). 
Figure R1. X-ray structure of human HDAC6 catalytic domain 2 (PDB entry 5EDU). General 
model of HDAC6 inhibition. Description of the common chemical structural features of HDAC6 
inhibitors and translation into UDCA synthetic conjugates. 
 
The chemical synthesis of the UDCA-HDAC6i molecules started with the 
coupling reaction of UDCA (1) with amines 2 to yield amide esters 3. Hydrolysis 
of these latter intermediates and in situ reaction with hydroxylamine permitted the 





#3-6 and #10, which possess different lengths and stereoelectronic features 





























































































In particular, these candidates incorporate alkyl, phenyl, heteroaryl and 
chiral groups in their respective spacers. Alternatively, hydrolysis of esters 3 
permitted the preparation of carboxylic acids 4, whose subsequent coupling with 
orthophenylenediamines 7 yielded amide candidates UDCA-HDAC6i #7, #8. In 
other examples, the spacer between the chelating group and the UDCA 
component was further elongated by an additional hydrolysis-coupling sequence 
thus yielding esters 6. Deprotection of these methyl esters and reaction with 
hydroxylamine permitted the isolation and characterization of candidates UDCA-
HDAC6i #2, #9. In summary, the synthetic scheme shown in Figure R2 yielded 
an ensemble of potential HDAC inhibitors possessing different spacers, chelating 
groups, and sharing an UDCA moiety as a common hydrophobic terminal cap. 
Therefore, this focused ensemble of candidates covered the configurational 
space around the conformationally restricted UDCA moiety. 
 
R.2 General methods for the synthesis of UDCA-HDAC6is 
R.2.a.1) Coupling of UDCA with spacers  
 
Scheme R1. General example of peptide coupling reaction of UDCA with aminoester spacers. 
 
To a solution of UDCA (393 mg, 1 mmol) in N,N-Dimethylformamide (DMF) (2.5 





and 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate   
(TBTU) (385 mg,1.2 mmol) were added. The solution was brought to 0 °C in an 
inert atmosphere and a solution of Et3N (0.5 mL) in DMF (0.6 mL) with a 
concentration of 3.26 M was added dropwise. Reaction was followed by thin layer 
chromatography. The reaction mixture was stirred for 3 hours. The solvent was 
then evaporated under reduced pressure, and the residue was dissolved in ethyl 
acetate (20 mL) and washed successively with 1N HCl (3 × 10 mL), saturated 
NaHCO3 (2 × 10 mL) and saturated NaCl (1 × 10 mL). The organic phase was 
dried over MgSO4 and evaporated under reduced pressure. The solid obtained 
was purified by chromatography obtaining the desired product. Compounds (3a-
f) were obtained following this method. 
 
R.2.a.2) Synthesis of hydroxamic acids 
 
 
Scheme R2. General example of the synthesis of hydroxamic acids from UDCA ester 
derivatives. 
 
To a solution of hydroxylamine hydrochloride (695 mg, 10 mmol) and 
phenolphthalein (1 mg) in dry methanol (5 mL) at 0°C under inert atmosphere, an 





37 mmol, 5 mL) was added dropwise until a permanent color switch to intense 
pink color. Then, the corresponding methyl or ethyl ester 3 (1 mmol) dissolved in 
dry methanol (1 mL) was added followed by addition of 1 mL of the previously 
prepared sodium methoxide suspension. Reaction was monitored by thin layer 
chromatography. The reaction mixture was stirred for 90 hours. Subsequently, 
distilled water (10 mL) was added and the reaction medium was acidified with 
glacial acetic acid. The product was then extracted with diethyl ether (3 × 20 mL) 
and the combined organic fractions were dried over MgSO4 and evaporated 
under reduced pressure. The product thus obtained was redissolved in methanol 
(1 mL) and precipitated with water. This precipitate was filtered and washed with 
water and diethyl ether to obtain the desired product. Compounds UDCA-HDAC6i 
#1, #3, #4, #5, #6 and #10 were obtained following this method. 
 
R.2.b.1) Hydrolysis of methyl ester 3 
 
Scheme R3. Reaction scheme of hydrolysis of UDCA ester derivatives. 
 
A solution of NaOH (2.15 mmol) in distilled water (4.35 mL) was slowly added to 
a solution of the corresponding UDCA ester derivative 3, (1 mmol) in acetone 
(4.35 mL). The mixture was stirred for 5 hours. The reaction mixture was then 





formed precipitate was filtered and washed successively with cold water, thereby 
obtaining the desired product. Compound 4a was obtained following this method. 
 
R.2.b.2) Synthesis of tert-butyl (3-amino- [1,1'-biphenyl] -4-yl) carbamate: D 
 
 
Scheme R4. Reaction scheme of the synthesis of tert-butyl (3-amino- [1,1'-biphenyl] -4-yl) 
carbamate. 
 
To a solution of 4-bromo-2-nitroaniline A (2.4 g, 11.05 mmol) and Boc-anhydride 
(di-tert-butyl dicarbonate) (5.08 mL, 22.11 mmol) in THF (20 mL) a catalytic 
amount of DMAP (4-dimethylamino pyridine) was added. The reaction was stirred 
for 90 minutes at room temperature. The solvent was then evaporated at low 
pressure and the oil obtained was dissolved in THF (10 mL). NaOH (10 mL, from 
a 2N solution) was then added and the reaction was stirred for 18 hours at 65°C. 
Afterwards, NaOH (400 mg, 10 mmol) was added and the reaction was stirred for 
additional 4 hours at 65°C. The progress of the reaction was monitored by thin 
layer chromatography. The solvent was removed in vacuo yielding a solid 





the desired product as a yellow solid B, which was used directly for the next 
reaction step to obtain C.  
Pd(PPh3)4 (400 mg, 0.346 mmol) was added to a reaction mixture in 
DME/H2O (2:1,5 mL) containing the corresponding tert-butyl carbamate B (1 g, 
3.15 mmol), obtained above, phenylboronic acid (423 mg 3.46 mmol) and sodium 
carbonate (492 mg, 4.73 mmol). The solution was stirred for 20 hours at 110°C 
and under inert atmosphere. After this reaction time, water was added, and the 
product was extracted with ethyl acetate (3 x 20 mL). The organic phases were 
combined and washed with water (2 x 10 mL), dried over magnesium sulfate, 
filtered and the solvent was evaporated under reduced pressure. The yellow solid 
thus obtained was purified by column chromatography obtaining the desired 
product C.  
The last step involved the reduction of the group nitro to obtain the 
corresponding primary amine, which was carried out using a modular catalytic 
hydrogenator (H-Cube Pro of THALESNano) and a Ni/Ra supported cartridge 
catalytic system. Compound C was dissolved in 500 mL of MeOH and passed 
through the catalyst system at a flow rate of 1 mL/min, 50°C and under a pressure 
of 10 bar. The solvent was removed in vacuo giving the desired product D as a 









R.2.b.3) Coupling of benzamide chelating groups  
 
Scheme R5. General example of the coupling of orthophenylenediamines. 
 
To a solution of the carboxylic acid 4 obtained in b.1 (206 mg, 0.38 mmol) in DMF 
(2.5 mL), the corresponding orthophenylenediamine (0.38 mmol) and TBTU (148 
mg, 0.46 mmol) were added. The solution was brought to 0°C in an inert 
atmosphere and a solution of Et3N (0.2 mL) in DMF (0.24 mL) with a 
concentration of 3.26 M was added dropwise. The mixture was stirred for 3 hours 
at 0°C. The reaction was monitored by thin layer chromatography. The solvent 
was then evaporated under reduced pressure, and the residue was dissolved in 
ethyl acetate (7.5 mL) and washed successively with 1 N HCl (3 × 5 mL), 
saturated NaHCO3 (2 × 5 mL) and saturated NaCl (1 × 5 mL). The organic phase 
was dried over MgSO4 and then evaporated under reduced pressure. The solid 
obtained was purified by column chromatography obtaining the desired product. 
Compound UDCA-HDAC6i #8 and N-BOC protected precursor of UDCA-HDAC6i 








R.2.b.4) Deprotection of the tert-butoxycarbamate 
 
Scheme R6. Reaction scheme of the carbamate deprotection of N-BOC protected UDCA-
HDAC6i #7. 
 
A solution of 4N HCl in dioxane (0.3 mL) was added dropwise to a suspension of 
the N-BOC protected compound (53 mg, 0.067 mmol) in a mixture of CH2Cl2 (0.63 
mL) and dioxane (0.63 mL). The progress of the reaction was monitored by thin 
layer chromatography. The mixture was kept under stirring for 3 hours. The 
solvent was then evaporated under reduced pressure. The solid thus obtained 
was suspended in AcOEt (10 mL) and washed with saturated NaHCO3 solutions 
(3 x 5mL) and NaCl (3 x 5mL), then dried over magnesium sulfate, filtered and 
evaporated. Finally, it was dissolved in MeOH and precipitated in Et2O, obtaining 










R.2.c.1) Coupling of the spacers 
 
 
Scheme R7. General scheme of the peptide coupling of aminoester spacers. 
 
To a solution of the corresponding carboxylic acid (0.38 mmol) in DMF (2.5 mL) 
the hydrochloride of methyl 4-(aminomethyl)benzoate (76 mg, 0.38 mmol) and 
TBTU (148 mg, 0.46 mmol) were added. The solution was brought to 0°C in an 
inert atmosphere and a solution of Et3N (0.2 mL) in DMF (0.24 mL) with a 
concentration of 3.26 M was added dropwise. Reaction was monitored by thin 
layer chromatography. The mixture was stirred for 3 hours. The solvent was then 
evaporated under reduced pressure, and the residue was dissolved in ethyl 
acetate (7.5 mL) and washed successively with 1N HCl (3 x 5 mL), saturated 
NaHCO3 (2 x 5 mL) and saturated NaCl (1 x 5 mL). The organic phase was dried 
over MgSO4 and evaporated under reduced pressure. The solid obtained was 
purified by chromatography obtaining the desired product. Compounds 6a and 








R.2.c.2) Synthesis of hydroxamic acids 
 
 
Scheme R8. General scheme of the synthesis of hydroxamic acids. 
 
To a solution of hydroxylamine hydrochloride (139 mg, 2 mmol) and 
phenolphthalein (1 mg) in dry methanol (5 mL) at 0°C under inert atmosphere, an 
aliquot of previously prepared suspension of sodium methoxide in methanol (2.0 
g, 37 mmol, 5 mL) was added dropwise until a permanent intense pink color was 
observed. Then, the corresponding methyl ester (0.2 mmol) dissolved in dry 
methanol (0.2 mL) and 1 mL of the previously prepared sodium methoxide 
suspension were added. The evolution of the reaction was monitored by thin layer 
chromatography. The reaction mixture was stirred for 90 hours. Subsequently, 
distilled water (2 mL) was added and the reaction mixture was acidified with 
glacial acetic acid. The product was then extracted with diethyl ether (3 × 5 mL) 
and the organic fractions were combined and dried over MgSO4 and evaporated 
under reduced pressure. The product thus obtained was redissolved in methanol 
(1 mL) and precipitated with water. This precipitate was filtered and washed with 
water and diethyl ether to obtain the desired product. Compounds UDCA-HDAC6i 






R.3 UDCA-HDAC6is exhibit binding affinities for HDAC6 CD1 and C2 in 
silico and UDCA is determinant in these interactions 
The potential HDAC6 inhibitory capacity of this new UDCA derivatives was first 
evaluated in silico with a docking model based on the crystallographic structure 
of human HDAC6 CD2 (PDB code: 5EDU) (Figure R1 and R3).  
 
Figure R3. In silico docking studies. Graphical representation of the binding of different UDCA-
HDAC6is on human HDAC6 CD2. The values of the score functions for each inhibitor are 





According to our results, eight of the ten designed compounds presented 
significant binding affinities for HDAC6, being UDCA-HDAC6i #1, #2 and #9 the 
compounds that displayed the highest energy scores (-8.3, -7.9 and -9.4 kcal/mol, 
respectively; Figures R3 and R4). Interestingly, these three compounds oriented 
the tetracyclic skeleton scaffold of UDCA towards the same region of the protein 
surface (Figures R3 and R4).  
Figure R4. Graphical representation of the orientations of UDCA hydrocarbon skeleton in the 
different UDCA-HDAC6is (yellow #9, green #1, blue #2, grey #4, #10, #6, #5 and #3) docked to 
the CD2 domain of human HDAC6. Dashed yellow lines represent hydrogen bond interactions 
between hydroxyl groups of UDCA and different amino acids located in the surface cavities of the 
enzyme. The table displays all the predicted binding energies reported in the docking studies for 
the UDCA-HDAC6is.  
 
Based on this observation, we decided to carry out a more detailed 
analysis of the binding modes of all compounds in order to understand the 
potential contribution of the different pharmacologically active substructures 
conforming each inhibitor (i.e., UDCA and chelating group) to the overall binding 






Figure R5. Schematic representation of the workflow followed to determine the contribution of 
the different substructures to the total binding affinity of each UDCA-HDAC6i. 
 
For that purpose, we decomposed the total binding energy of each synthetic 
derivative into the contribution of the following descriptors to the final score. 
 XP GScore: Total GlideScore, sum of XP terms 
 Lipophilic EvdW: Lipophilic term derived from hydrophobic grid potential 
and fraction of the total protein-ligand vdW energy. 
 PhobEn: Hydrophobic enclosure reward. 
 PhobEnHB: Reward for hydrophobically packed H-bond. 
 PhobEnPairHB: Reward for hydrophobically packed correlated H-bonds. 
 HBond: ChemScore H-bond pair term. 
 Electro: Electrostatic rewards. 
 SiteMap: SiteMap ligand/receptor non-H bonding polar/hydrophobic and 





 π Cat: Reward for pi-cation interactions. 
 ClBr: Reward for Cl or Br in a hydrophobic environment that pack against 
Asp or Glu. 
 LowMW: Reward for ligands with low molecular weight. 
 Penalties: Polar atom burial and desolvation penalties, and penalty for 
intra-ligand contacts. 
 HBPenal: Penalty for ligands with large hydrophobic contacts and low H-
bond scores. 
 ExposPenal: Penalty for exposed hydrophobic ligand groups. 
 RotPenal: Rotatable bond penalti. 
 EpikState Penalty: Penalty for ionization or tautomeric states calculated by 
Epik. 
 Corrected GScore: XP GScore corrected by elimination of spurious terms 
generated by structure fragmentation. 
 
Next, taking as starting point the optimal binding mode of each inhibitor, we 
separately calculated the binding energy of each substructure on its initial 
position, decomposing this energy into the previously mentioned descriptors. 
Finally, after correction of the spurious terms generated by separation of the 
substructures (i.e., rotational penalties, low molecular weight rewards…) we 
obtained the contribution of each substructure to the total binding energy of the 







Table R1. Contribution of the different molecular descriptors (see text) to the total binding affinities 





It is interesting to note that the difference between the obtained initial XP 
GScore for each compound and the sum of the corrected XP GScores for its 
forming substructures was in all cases ≤ 0.8 kcal/mol, confirming the reliability of 
the method. Importantly, we observed that in the cases of UDCA-HDAC6i #1, #2 
and #9, the three compounds that displayed the highest binding energies, the 
contribution of UDCA to the final binding energy was approximately one third of 
the total value, being this contribution mainly integrated by van der Waals 
interactions and hydrogen bonds. (Table R1). 
As mentioned before, one of the main distinctive features of HDAC6 with 
respect to other HDACs is the presence of tandem catalytic domains CD1 and 
CD2. Although most catalytic potential of HDAC6 has been commonly attributed 
to CD2,180 two recently published studies using different HDAC6 constructs in 
directed mutagenesis, activity and crystallography experiments, have pointed out 
the potential importance of HDAC6 CD1 for HDAC6 catalytic activity.118,119 For 
this reason, we decided to submit our UDCA-HDAC6is to docking simulations on 
HDAC6 CD1 in order to evaluate their inhibitory potential on this domain. Since 
there is not crystallographic structure of human HDAC6 CD1 available, we 
attempted to generate a homology model of the human catalytic domain based 
on the X-ray structure of HDAC6 CD1 from zebrafish (PDB code: 5G0G). For that 
purpose, we aligned the predicted secondary structures of both sequences (i.e., 
human HDAC6 CD1 and zebrafish HDAC6 CD1) (Figure R6) and generated a 
knowledge-based 3D model using Prime181,182 software included in the Maestro 

























































































































































Once we obtained the 3D homology model, we optimized and minimized 
the protein structure and used it in docking experiments with the previously 
described synthetic UDCA derivatives. Our results (Table R2) showed that as 
observed for HDAC6 CD2, UDCA-HDAC6i #9 and #2 maintained high affinity for 
CD1. On the other hand, while UDCA-HDAC6i #1 showed lower affinity for CD1 
when compared to CD2, compound #10 showed substantially higher affinity for 




XP GScore  
(kcal/mol) 
Rank 
XP GScore  
(kcal/mol) 
Rank 
#1 -6.3 (4) -8.3 (2) 
#2 -7.4 (3) -7.9 (3) 
#3 -5.1 (8) -3.9 (6) 
#4 -5.3 (7) -4.8 (4) 
#5 -5.6 (6) -3.9 (6) 
#6 -5.9 (5) -4.2 (5) 
#9 -8.6 (1) -9.4 (1) 
#10 -7.9 (2) -4.7 (4) 
 
Table R2. Predicted binding affinities (XP GScore) of the different UDCA-HDAC6is for the 
catalytic site of human HDAC6 CD1 homology model. The data obtained for HDAC6 CD2 are 









R.4 UDCA actively contributes to the selective HDAC6 inhibitory activity of 
UDCA-HDAC6is 
We confirmed by immunoblot the previously reported21 overexpression of HDAC6 
in human cystic cholangiocytes compared to normal human cholangiocytes in 
culture (Figure R7). 
 
Figure R7. Representative immunoblot and graphical representation of the relative HDAC6 
protein expression in human PLD and normal cholangiocytes. 
 
Since acetylated α-tubulin is one of the main deacetylation targets of 
HDAC6, the levels of acetylated α-tubulin in cholangiocytes are considered a 
good marker of HDAC6 expression and activity on these cells. Therefore, in order 
to evaluate the HDAC6 inhibitory potential of UDCA-HDAC6is, the levels of 
acetylated α-tubulin were measured by immunoblot in cell cultures of human 





conjugates (Figure R8). In addition, acetylation levels of lysine 9 of the nuclear 
histone 3 (H3K9) were measured as a control of selectivity (negative control).  
 
Figure R8. In vitro HDACi activity in PLD cells. Representative immunoblot of the acetylation 
levels of α-tubulin and Histone 3 (H3K9) after 24h treatment with 2 μM of each compound. 
Chelating agent refers to the spacer ended on a Zn(II) chelating motif directly bonded to UDCA 
in UDCA-HDAC6i #1. 
 
Our results (Figure R8) revealed that at low concentration (2 M), at least 
four of the synthetized UDCA conjugates (#1, #2, #6 and #9) induced an increase 
in the levels of acetylated α-tubulin in cystic cholangiocytes, without affecting the 
acetylation of the nuclear H3K9 residue (negative control), thus indicating 
selective inhibitory activity on HDAC6. In contrast, one of the new synthetized 
UDCA conjugates (#8) substantially increased the levels of H3K9 in cystic 
cholangiocytes without increasing the acetylation of α-tubulin, being a potential 
inhibitor of nuclear HDACs (Figure R8). It is interesting to note that, comparison 
between the in silico predicted binding energies of the aforementioned UDCA 
conjugates on HDAC6 CD2 and their effect on the HDAC6-dependent levels of 





(r2=0.8031) for these two parameters, confirming the predictive accuracy of our 
computational approach (Figure R9). 
 
Figure R9. Experimental validation of the in silico docking model. Graphical representation of 
predicted biding energies versus the normalized HDAC6 inhibitory activity in PLD cells. 
 
Next, the inhibitory capacity of UDCA-HDAC6i #1, #2, #6, #8 and #9 on 
purified HDAC1 and HDAC6 enzymes was measured by monitoring the dose-
dependent deacetylation of a fluorogenic acetylated peptide (Figure R10). Data 
showed that UDCA-HDAC6i #1, #2, #6 and #9 displayed nanomolar half-maximal 
inhibitory concentration (IC50) values (58 nM, 56.1 nM, 82.1 nM, 4.26 nM, 
respectively) for HDAC6 inhibition, concomitantly with a high degree of selectivity, 
calculated as the HDAC6i/HDAC1i ratio, particularly in the case of compounds 
#1, #2, and #9 (Figure R10). On the other hand, UDCA-HDAC6i #8 showed both 






Figure R10. Dose response curves and IC50 values of the inhibitory activity of UDCA-HDAC6i 
#s #1 (n=9), #2 (n=9), #6 (n=3), #8 (n=3) and #9 (n=3) on HDAC6 and HDAC1. For curve fitting 
and IC50 calculation, log (inhibitor) versus normalized response with variable slope equation was 








Importantly, UDCA itself did not exhibit any direct HDAC inhibitory activity; 
however, its covalent bonding with the structure of the chelating group in order to 
form UDCA-HDAC6i #1, significantly increased (~12 fold) its HDAC6 inhibitory 
capacity (IC50 = 58 nM) with respect to that measured for the isolated chelating 
group unit (IC50 = 689 nM). In addition, the effect of UDCA-HDAC6i #1 and #2 
was also evaluated on purified HDAC2-5 and HDAC7-11 enzymes, showing 
similar inhibitory capacity than in HDAC1 and significantly less compared to 
HDAC6 (Table R3). 
 
Table R3. IC50 values of UDCA-HDAC6i #1, #2, #6, #9 and #8 in HDAC (1-11). ND: non-
determined. (-), not analyzed. 
 
All these data demonstrate that the presence of UDCA in the UDCA-
HDAC6i structure provides a synergic effect on their inhibitory capacity on 
HDAC6, pointing out the active and critical contribution of UDCA to the 





R.5 Chemical and structural factors that determine inhibitory activity and 
selectivity of UDCA-HDAC6is 
The analysis of the interactions between the individual protein residues of human 
HDAC6 CD2 and the different UDCA-HDAC6is revealed important information 
about some events that seem to be critical to determine the activity and selectivity 
of UDCA-HDAC6is (Table R4). First, our docking experiments showed that, 
contrary to what was first expected, in 7 of the 8 docked compounds (UDCA-
HDAC6i #1, #2, #3, #4, #6, #9, and #10), the hydroxamate moiety exhibited a 
monodentate coordination geometry to the Zn(II) cation of HDAC6 CD2 by 
interaction between the carboxyl group of the inhibitor and the metal ion of the 
enzyme. According to this, in 6 of the mentioned cases (#1, #2, #4, #6, #9, and 
#10), the NH group of the hydroxamic acid preferentially established a hydrogen 
bond with the carboxamide group of glycine 619. This generated a shift of the 
hydroxy group of the hydroxamate far from the coordination sphere of Zn(II) 
cation, therefore avoiding the possibility of establishing a classical bidentate 






Table R4. Schematic representation of the main protein-ligand interactions observed in the 
docking model of human HDAC6 CD2. 
 
Importantly, the three compounds that exhibited the strongest binding 
energies as well as the highest levels of activity and selectivity (UDCA-HDAC6i 
#1, #2 and #9) were the ones containing one or two 1,4-phenylene moieties 
acting as the linker of the inhibitor, and a hydroxamic acid as the Zn(II) chelating 





of UDCA towards the same region of the protein surface (Figures R3 and R4). 
When comparing the interactions displayed by these three compounds we could 
observe some interesting similarities. In this regard, these three compounds 
established π-π interactions between the 1,4-phenylene groups of the inhibitors 
and phenylalanine 620 flanking the hydrophobic channel that connects the outer 
rim with the internal active site (Table R4). Importantly, in the three cases 
hydrogen bonds were established between the hydroxy groups located in the 
hydrocarbon skeleton of UDCA and different aminoacids of the protein surface. 
Finally, these three compounds interacted by hydrogen bonding with tryptophan 
496 located in one of the outer cavities surrounding the active site (Figure R4 and 
Table R4).  
Interestingly, structural comparison of UDCA-HDAC6i #1 with UDCA-
HDAC6i #6 revealed that the respective distance between C-24 and the 
carboxamide group of the hydroxamate moiety were 7.64 Å and 8.66 Å 
respectively (Figure R11), thus showing a difference of only 1 Å. 
 
Figure R11. Structural comparison of UDCA-HDAC6i #1 and #6. Dashed pink line shows the 






Furthermore, the only structural difference between UDCA-HDAC6i #1 and #2 is 
the presence of a glycine residue in UDCA-HDAC6i #2 that elongates the length 
of the linker around 2.5 Å in respect to UDCA-HDAC6i #1. Accounting for this, 
linker length in these three cases would be UDCA-HDAC6i #2 > UDCA-HDAC6i 
#6 > UDCA-HDAC6i #1. However, HDAC6 selectivity for these compounds 
appeared to be #1 > #2 >>> #6. Therefore, since they share the same chelating 
group (i.e., hydroxamic acid), the same van der Waals cap (i.e., UDCA) and 
possess similar linker lengths, it seems that the chemical nature of the spacer is 
critical to determine selectivity of these compounds, and in this regard 1, 4-
phenylene groups provide substantial advantage towards HDAC6 selectivity 
when compared to alkyl groups. Although there are some important differences 
in terms of HDAC6 activity between inhibitors containing paraphenyl spacers and 
compound carrying alkyl spacer (i.e., UDCA-HDAC6i #1 (IC50 = 58 nM), #2 (IC50 
= 56,1 nM) and #9 (IC50 = 4.26 nM) versus UDCA-HDAC6i #6 (IC50 = 82.1 nM)) 
this difference becomes much more exacerbated when comparing 
HDAC6/HDAC1 selectivity between these two type of compounds (i.e., #1 
(HDAC6/HDAC1 = 174), #2 (HDAC6/HDAC1 = 160) and #9 (HDAC6/HDAC1 = 
3574) vs #6 (HDAC6/HDAC1 = 31)). For this reason, we hypothesized that, at 
least for this type of compounds, HDAC6 selectivity would be in part dictated by 
the optimized HDAC6 activity, but largely by the suboptimal capacity to bind the 
catalytic domain of other HDAC isoforms. Thus, to test this hypothesis we carried 
out the alignment of the catalytic domains of human HDAC1, 2, 3, 4, 7, 8 and 
zebrafish HDAC10 (PDB entries: 5ICN, 6G3O, 4A69, 4CBT, 3ZNR ,5VI6 and 








Figure R12. Upper and side views of the three-dimensionally aligned active sites of different 
HDAC isoforms (HDAC1, 2, 3, 4, 6, 7, 8 and zebrafish HDAC10 (PDB entries: 5ICN, 6G3O, 4A69, 






Alignment of the catalytic domains of the different isoforms revealed some 
differences in the architecture of the outer rim, the hydrophobic channel, and the 
active site (Figure R12). In this regard, while isoforms 2, 6 and 8 share similar 
features in terms of depth and width of the hydrophobic channel, isoforms 4 and 
7 possess a wider cavity and isoform 10 becomes wider at the bottom of the 
channel. In addition, isoforms 1 and 3 extend the hydrophobic channel deeper 
into the protein internal face. Interestingly, in all cases the Zn(II) cation is located 
in a very similar position. However, although there are some differences in the 
particular architectures of the hydrophobic channels of the different HDAC 
isoforms, these are not enough to explain the substantial differences in terms of 
selectivity observed between UDCA-HDAC6i #6 and compounds carrying 1, 4-
phenylene spacers (Figure R10 and table R3). Outstandingly, analysis of the 
surface topography of the catalytic sites of the different HDAC isoforms aligned 
to our docking model revealed fundamental information to understand HDAC6 
selectivity in UDCA-HDAC6is and most probably in other HDAC inhibitors 
(Figures R12 and R13). In this regard, we observed that the surface cavity 
preferentially occupied by the UDCA moiety in the compounds containing 1, 4-
phenylene linkers is not present in the other HDAC isoforms, while the other two 
cavities occupied by less active/selective UDCA-HDAC6is (UDCA-HDAC6i #6) 






Figure R13. 3D structural alignment of the catalytic domains of different HDAC isoforms with the 
docking model of human HDAC6 CD2. In blue, surface region in which the three most 
active/selective UDCA-HDAC6is preferentially accommodate UDCA in HDAC6. 
 
Accordingly, sequence alignment of the mentioned HDAC isoforms confirmed a 
very low degree of sequence identity in the mentioned region between HDAC6 




































































































































































































































R.6 Potency and selectivity, pharmacokinetic properties and synthetic cost 
make UDCA-HDAC6 #1 the best candidate for potential clinical translation 
Once the HDAC6 inhibitory potency and selectivity were confirmed on four of the 
newly synthesized UDCA-HDAC6is, we had to select the best candidate for 
further characterization and evaluation of its therapeutic potential in vivo. 
Although UDCA-HDAC6i #9 showed the highest HDAC6i activity and selectivity 
values in enzymatic assays, we considered some other important factors for the 
selection of the lead compound. First, the synthetic route for UDCA-HDAC6i #9 
is substantially longer than that for other UDCA-HDAC6is. For this reason, the 
synthesis of UDCA-HADC6i #9 in larger scales would come out to be very 
expensive, raising some concerns about its clinical translation. For example, 
while UDCA-HDAC6i #1 requires only two synthetic steps with an overall yield of 
51%, UDCA-HDAC6i #9 needs four steps what requires more starting materials 
and leads to a substantial drop in the overall yield to only 27 % (Figure R2). 
The pharmacokinetic properties of the compound should also be considered 
for the final selection. One of the main components of our therapeutic strategy 
was to benefit from the intrinsic hepatotropic features of UDCA to target and 
maintain the compound into the enterohepatic circulation after oral administration 
and gastrointestinal absorption. In order to reduce the number of animals used 
for experimentation, we applied QikProp software included in Maestro package 
10.4 to perform an in silico prediction of several pharmacokinetic parameters for 
all the designed UDCA-HDAC6is, obtaining considerably better values for UDCA-































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Furthermore, while UDCA-HDAC6i #1 displayed values within the recommended 
range for all parameters except one, UDCA-HDAC6i #9 felt out of the 
recommended range in eight different parameters (Table R5). Nevertheless, 
despite UDCA-HDAC6i #9 inhibitory activity was higher in the enzymatic assays 
(Figure R10), when compared to UDCA-HDAC6i #1, activity assays performed in 
PLD cells revealed a similar degree of α-tubulin acetylation at the same 
concentrations (Figure R8). Last but not the least, one of the main parts of our 
hypothesis was to maintain the therapeutic potential of UDCA for PLD treatment 
within our molecules. In this sense we hypothesized that UDCA could trigger 
some of its therapeutic effects either directly as part of the UDCA-HDAC6#, or 
upon hepatic metabolism of the amide bond and further liberation of an intact 
UDCA molecule. However, a potential limitation for the dual activity of these 
compounds could be the difference in the concentration ranges required for their 
individual activities (µM for UDCA versus nM for UDCA-HDAC6#s), which was 
clearly most exacerbated in the case of UDCA-HDAC6i #9. Taking into account 
all of these considerations, we selected UDCA-HDAC6i #1 for further 
investigations about its therapeutic potential for PLDs. 
 
R.7 UDCA-HDAC6i #1 halts hepatorenal cystogenesis in PCK rats 
The therapeutic value of UDCA-HDAC6i #1 was evaluated in PCK rats (Pkhd1 
mutant), a well-characterized animal model that spontaneously develops 
hepatorenal cystogenesis overtime.183,184 Eight weeks-old PCK rats were treated 






Figure R15. Representative livers of a control rat, as well as non-treated and a UDCA-HDAC6i 
#1-treated PCK rats. Graphical representation of the relative comparisons of liver weight, total 
body weight, liver/body weight ratio, and serum albumin concentration in the three assayed 
groups. Statistical unpaired two-tailed t test analysis was applied to determine significance in all 
cases with exception of PCK treated versus non treated liver to body weight in which unpaired 
one-tailed t test analysis was applied. 
 
Remarkably, the characteristic hepatomegaly that PCK rats develop over time 





HDAC6i #1. In this regard, liver to body weight ratio was found also reduced 
compared to untreated PCK rats (Figure R15). Nevertheless, these effects were 
associated with a significant improvement in liver function, as reflected by the 
increased albumin levels observed in serum. (Figure R15).  
 
 
Figure R16. Representative kidneys of a control rat, as well as non-treated and a UDCA-HDAC6i 
#1-treated PCK rats. Graphical representation of the relative comparisons of kidney weight, 
kidney/body weight ratio, and serum urea concentration in the three groups. Statistical unpaired 






In agreement, treated animals showed a significant reduction in disease-
associated nephromegaly as well as in the kidney to body weight ratio (Figure 
R16). Importantly, chronic treatment of PCK rats with UDCA-HDAC6i #1 resulted 
in a significant reduction of the increased serum urea levels observed in PCK 
rats, to values similar to the ones observed in healthy rats, suggesting a 
substantial improvement in renal function upon treatment (Figure R16). 
In order to obtain some insights into the pharmacokinetic features of UDCA-
HDAC6i #1 we measured the biodistribution of this compound to liver, bile, 
systemic and portal blood of treated animals at the moment of sacrifice (Figure 
R17). 
 
Figure R17. Analysis of UDCA-HDAC6i #1 pharmacokinetics. (A) Schematic representation of 
the enterohepatic circulation. (B) Graph represents the bioavailability profile of UDCA-HDAC6i #1 
on different portal blood (n=8), liver (n=8), bile (n=7, statistical outlier removed) and peripheral 






These animals presented UDCA-HDAC6i #1 in liver, bile, systemic and portal 
blood, but particularly in bile (Figure R17). 
Next, we analyzed the levels of acetylated α-tubulin in the livers and kidneys 
of treated and non-treated PCK rats in order to assess the pharmacological 
targeting of the synthetic derivative (Figure R18). Our results show that levels of 
acetylated α-tubulin were found increased both in liver and kidney of UDCA-
HDAC6i #1-treated animals compared with PCK control rats, confirming their 
target pharmacological effect on these organs in vivo (Figure R18). 
 
Figure R18. Representative immunoblot of the levels of acetylated α-tubulin in liver and kidney 
of PCK treated (n=8) and non-treated (n=12) rats. Graph represents the relative amount of 
acetylated α-tubulin in liver and kidney using total tubulin as normalizing control. For statistical 





R.8 UDCA-HDAC6i #1 modulates the bile acid pool and increases the levels 
of unconjugated UDCA in PCK rats 
The concentration and composition of bile acids was evaluated in liver, bile, as 
well as in peripheral and portal blood of treated and non-treated PCK rats. As 
previously described by our group,4 the total bile acids concentration was found 
increased in both liver and peripheral blood of PCK rats compared to normal 
control animals, and these values were not modified in PCK rats treated with 
UDCA-HDAC6i #1 (Figure R19). On the other hand, no changes in the total bile 
acids concentration were found in portal blood and bile between the experimental 
groups (Figure R19). 
 
Figure R19. Total bile acids concentration in liver, portal blood, bile and peripheral blood of SD 
rats (WT) and PCK rats non-treated or treated with UDCA-HDAC6i #1. Statistical unpaired two-
tailed t test was applied to determine significance. 
 
In contrast, substantial differences in the composition of the bile acid pool were 





described4 decrease in UDCA concentration in the liver of PCK rats, compared 
to normal animals, was reversed upon UDCA-HDAC6i #1 treatment (Figure R20).  
 
Figure R20. UDCA concentration in liver, portal blood, bile and peripheral blood of SD rats (WT) 
and PCK treated and non-treated rats with UDCA-HDAC6i #1. Statistical unpaired two-tailed t 
test was applied to determine significance. 
 
Moreover, increased levels of UDCA were found in portal and peripheral blood, 
as well as in bile of PCK rats treated with UDCA-HDAC6i #1 compared to both 
normal and PCK untreated animals (Figure R20). Likewise, a normalization of 
major unconjugated bile acids (i.e., CA, a/bMCA, SLCA in liver, CA and HyoDCA 







Table R6. Relative abundancies of conjugated bile acids in liver, portal blood, bile and peripheral 
blood of SD rats (WT) and PCK treated and non-treated rats with UDCA-HDAC6i #1. For 
statistical analysis, two-tailed unpaired t test was performed. Abbreviations: TUDCA, 
tauroursodeoxycholic acid; TCA, taurocholic acid; Ta/bMCA, tauro α/β murocholic acid; TQDCA, 
taurochenodeoxycholic acid; GUDCA, glycoursodeoxycholic acid; GCA, glycocholic acid; 
GQDCA, glycochenodeoxycholic acid; UDCA, ursodeoxycholic acid; CA, cholic acid; a/bMCA, 





R.9 UDCA-HDAC6i #1 halts liver cystogenesis in vivo, and this event is 
linked to the restoration of the cholangiocyte primary cilium length and 
inhibition of cell proliferation 
The histological analysis of the liver sections of three different lobes revealed a 
reduction of the relative cystic area in UDCA-HDAC6i #1-treated animals 
compared with matched PCK rats without treatment (Figure R21).  
Figure R21. Representative images of hematoxylin eosin staining (scale bar = 500 µm) and CK19 
immunohistochemistry (scale bar = 250µm). Graph represents the cystic area relative to total 
tissue area of individual hepatic lobes (3 for each animal). Statistical unpaired two-tailed t test 





At the cellular level, UDCA-HDAC6i #1 restored the primary cilium length in cystic 
cholangiocytes in vitro (~40% increase), which was linked to its direct inhibitory 
effect on HDAC6 activity and the consequent increase of the levels of acetylation 
α-tubulin in the cilium (Figure R22). 
 
Figure R22. (A) Representative immunoblot of the effect of increasing doses of UDCA-HDAC6i 
#1 on the α-tubulin acetylation in cultured PLD cholangiocytes. GAPDH was used as a 
normalizing control. (B) Representative immunofluorescence images of acetylated α-tubulin. Cell 
primary cilia can be distinguished in green. Blue areas represent cell nuclei stained with DAPI. 
(C) Bar graph represents the mean ciliary length of basaline (n=23) or 2 µM UDCA-HDAC6i #1 
treated (n=21) normal human cholangiocytes, as well as baseline (n=30) and 2 µM UDCA-






In contrast, no changes in the primary cilium length were observed in normal 
cholangiocytes incubated with UDCA-HDAC6i #1 (Figure R22).  
Since the primary cilium promotes the epithelial cell polarity and prevents 
the cell cycle initiation,185,186 we analyzed the effect of UDCA-HDAC6i #1 on the 
proliferation of cystic cholangiocytes in monolayer cell cultures, and 3D cystic 
structures. As shown in Figure R23, UDCA-HDAC6i #1 inhibited the 3-
dimensional (3-D) growth of cystic cholangioids compared to control conditions. 
 
Figure R23. 3D culture in collagen type I of cysts isolated from PCK rats. The graph represents 
the relative circumferential area of individual non-treated (n=20) and 10 µM UDCA-HDAC6i #1 
treated (n=20) cyst-like structures along time. 
 
In accordance, UDCA-HDAC6i #1 inhibited the 2D cystic cholangiocyte 







Figure R24. (A) Determination by flow cytometry of the effect on cell proliferation of different 
treatments on cystic human cholangiocytes stained with CFSE. Bar graph represents the 
percentage of cell proliferation after 48 hours treatment with 10 µM UDCA (n=7), 100 µM UDCA 
(n=22), 2 µM UDCA-HDAC6i #1 (n=16), 10 µM UDCA-HDAC6i #1 (n=23), 10 µM chelating group 
(n=23) or 10 µM UDCA, and 10 µM chelating group combined treatment (n=7) relative to control 
(n=23) cystic cholangiocytes. (B) Representative immunoblot and (C) relative abundance of 
phosphorylated ERK1/2 in cystic human cholangiocytes at basaline (n=5) or under incubation 





Importantly, this anti-proliferative effect was significantly higher than the one 
observed upon combined treatment with the two pharmacologically active 
substructures that compose UDCA-HDAC6i #1 (i.e., UDCA plus HDAC6 
chelating group) (Figure R24), indicating the occurrence of fairly a superior 
therapeutic profile upon covalent coupling of these two elements. 
 
R.10 Hepatotropic properties of UDCA-HDAC6i #1  
We next studied the mechanisms of UDCA-HDAC6i #1 uptake by cystic 
cholangiocytes. For this purpose, cell models of liver-specific plasma membrane 
transporters were used in transport assays using specific substrates and 
inhibitors (Figure R25 and R26). 
 
Figure R25. Schematic example of a transport experiment. Ia: Incubation of cells with 100 µM 
uDCA-HDAC6i #1 in basaline conditions. Ib: Incubation of cells with 100 µM UDCA-HDAC6i #1 
in the presence of transporter inhibitor. IIa: Incubation of cells with 100 µM uDCA-HDAC6i #1 in 
after induced transporter overexpression. IIb: Incubation of cells with 100 µM uDCA-HDAC6i #1 






Figure R26. Identification of the molecular transporters involved in the uptake of UDCA-
HDAC6i #1.  (A) Bar graphs representing UDCA-HDAC6i #1 uptake in basaline and transporter 
overexpressing conditions in the presence or absence of a transporter inhibitor or a substrate 
competitor. Transporter overexpression was carried out on CHO cells for NTCP (n=4) and OCT3 
(n=5), transporters and in HepG2 cell line for OCT1 (n=4) transporter. (B) RT-qPCR analysis of 
the mRNA expression of NTCP, OCT1 and OCT3 transporters in normal (n=6) and cystic (n=6) 
human cholangiocytes. RPL22 gene was used as the normalizing control. Two-tailed t-test was 





Data showed that UDCA-HDAC6i #1 is effectively transported by the sodium-
dependent bile acid transporter NTCP (sodium-taurocholate cotransporting 
polypeptide) as well as the organic cation transporters OCT1 and OCT3 (Solute 
carrier family 22 members 1 and 3)  (Figure R26), two transporters commonly 
involved in the transport of cationic molecules. In parallel, we evaluated the 
expression of all these transporters in normal and cystic human cholangiocytes 
by RT-qPCR (Figure R26). According to our results, the expression of NTCP was 
found downregulated while OCT1 and OCT3 were found significantly upregulated 

























PLD represents a significant clinical, social and economic burden. Current 
therapeutic strategies include surgical procedures such as aspiration-
sclerotherapy or fenestration of the cysts in highly symptomatic patients, and/or 
systemic pharmacological treatment based on the use of somatostatin 
analogues. However, both surgical and pharmacological approaches show short-
term and modest beneficial effects without impacting on disease development 
and progression,2 and therefore liver transplantation remains as the only curative 
option. To date, several genetic defects and related molecular abnormalities 
triggering cystogenesis have been described, being currently considered 
potential targets for therapy.1,9 For instance, chronic treatment with UDCA inhibits 
hepatic cyst growth in experimental models of PLD and in a subset of patients 
with advanced PLD (CURSOR Phase II clinical trial), also improving their 
symptomatology.15,20 Oral administration of UDCA is well tolerated, safe and is 
currently the first-line therapy internationally approved for the treatment of PBC.27 
The beneficial effects of UDCA on PLDs have been linked to the ability of UDCA 
to increase the iCa2+ levels in cystic cholangiocytes, as well as to its choleretic 
properties, that enable it to wash out the increased concentration of cytotoxic and 
pro-mitotic bile acids in PLD livers. On the other hand, inhibition of the HDAC6 
activity has been proposed as a therapeutic strategy for PLD, as it prevents 
exacerbated deacetylation of -tubulin, directly contributing to stabilization of the 
primary cilium of cholangiocytes, restoration of ciliogenesis and cell polarity, and 
consequently inhibiting hepatic cystogenesis progression in vivo. However, the 
therapeutic benefits of both UDCA and HDAC6 inhibitors are partial, indicating 





The currently available HDAC6 inhibitors do not show preferential targeting 
to the liver, and in particular to biliary cells. Most HDAC6 inhibitors developed to 
date comprise on their structure an external cap that accommodates on the 
shallow cavities located on the protein surface followed by a hydrophobic linker 
ended on a Zn(II) chelating group that enters into the catalytic sites of HDAC6.62 
In this regard, HDAC6i molecules usually contain aromatic peptide derivatives 
and hydrocarbons acting as the closing cap of the inhibitor,128-130,187 which are 
prone to be released into systemic circulation after their hepatic metabolism. 
These residues have been largely demonstrated to be potentially toxic in humans; 
the most frequent manifestations of toxicity in clinical trials are fatigue, nausea, 
diarrhea and cardiotoxicity, including ventricular arrhythmia, which is perhaps the 
most worrisome adverse effect.188,189 Considering these limitations for 
combination therapies,190 and taking advantage of our experience in the design 
of HDAC inhibitors through rational computer aided approaches,62 we 
hypothesized that UDCA could be an appropriate external cap-acting building 
block for the development of new HDAC6 inhibitors with high selectivity, improved 
hepatotropism, low toxicity and additional therapeutic features, because:  
i) our in silico docking experiments indicate that UDCA may actively contribute to 
reinforce the inhibitory potential and selectivity of the hydrophobic linker plus the 
Zn(II) chelating group. This reinforcement occurs through the establishment of 
van der Waals interactions and hydrogen bonds between the two hydroxy groups 
present on the UDCA structure and the side chains of several amino acid 






ii) UDCA would provide hepatotropic features to these new UDCA-HDAC6i 
entities by promoting its enterohepatic transport through bile acid and/or organic 
cation transporters; 
iii) UDCA is usually conjugated with taurine (TUDCA) or glycine (GUDCA), also 
termed amidation, in  the carbon C-24 within hepatocytes.191,192 Therefore, this 
residue could be used as the conjugation site for the chelating group; 
iv) the gut (colon) microbiome deconjugates the taurine or glycine residues of 
UDCA,193 and consequently, UDCA-HDAC6i present in bile and entering the gut 
could be deconjugated by this process resulting in a secondary increase of the 
enterohepatic levels of UDCA that would provide additional therapeutic benefits.  
With all this information, we designed, synthesized and exhaustively 
characterized a new family of 10 UDCA derivatives. We applied these 10 
structures to docking experiments versus three-dimensional structure of human 
HDAC6 CD2. In these experiments, UDCA-HDAC6 #1, #2 and #9 showed 
considerably higher binding affinities for this catalytic domain than the other 
UDCA derivatives. Four of these compounds (UDCA-HDAC6 #1, #2, #6 and #9) 
exerted highly selective inhibitory activity on HDAC6 both in cell culture and 
enzymatic assays, while replacement of the hydroxamic acid contained on 
UDCA-HDAC6i #1 by the orthophenylenediamine present in UDCA-HDAC6i #8 
resulted in a complete switch in both the inhibitory activity and selectivity towards 
nuclear HDACs instead of HDAC6. It is interesting to note that, the accuracy of 
the computational docking approach was confirmed by comparison of the 
predicted in silico values versus the in vitro inhibitory effect, thus obtaining a 





Importantly, our data showed that UDCA itself has not significant HDAC 
inhibitory activity. However, its covalent coupling to the structure of the chelating 
group in order to form UDCA-HDAC6i #1 reduced one order of magnitude the 
IC50 value on HDAC6 with respect to the isolated chelating group. It is 
noteworthy that, the three UDCA-HDAC6i molecules displaying the highest in 
silico binding affinities to HDAC6 CD2 (i.e., UDCA-HDAC6i #1, #2, and #9) were 
also the ones showing the highest levels of activity and selectivity for HDAC6. 
Interestingly, these three molecules contained 1, 4-phenylene spacers and 
hydroxamates as chelating groups, and oriented the hydrocarbon skeleton of 
UDCA towards the same region of the protein surface. These features indicate 
that the reduced entropy derived from the preorganization of the steroidic scaffold 
of UDCA, the π-π stacking interactions and the particular geometry provided by 
the aromatic spacers help to accommodate and stabilize UDCA in a more 
favorable position to optimize interactions with amino acids located in the outer 
cavities of HDAC6 CD2. The interactions displayed by UDCA emerged as critical 
factors to reinforce the HDAC6i activity and selectivity of these compounds. In 
this regard, the difference in binding energies with the other compounds, which 
accommodated UDCA in other surface cavities, was more than 3 kcal/mol. In 
particular, the 3 most active/selective compounds established a hydrogen bond 
between the UDCA structure and tryptophan 496, a residue that has been 
recently demonstrated to be important for acetylated α-tubulin recognition by 
HDAC6 CD2.118 The contribution analysis of the different components of UDCA-
HDAC6i molecules to their energy of binding revealed that when analyzing the 
role of UDCA, both the lipophilic van der Waals interactions energies and the 





large energy differences between the 3 best scored compounds (i.e., UDCA-
HDAC6i #1, #2, and #9) and the other UDCA-HDAC6i molecules. 
Focusing in HDAC6 selectivity, structural alignment of different HDAC 
isoforms with our docking model of human HDAC6 CD2 revealed that the surface 
cavity preferentially occupied by the three most active/selective compounds 
remains buried and therefore not accessible in the other HDAC isoforms. This 
result is of particular interest because to date most published studies have 
focused attention on the hydrophobic channel and the surface rim in the search 
for HDAC6 selectivity, most probably because of the lack for any experimental 
data about HDAC6 3D structure. This lack of accurate structural information has 
limited further computer aided design of HDAC6 inhibitors to the use of homology 
models.129,187,194 In this regard, these models can be useful tools to predict and 
optimize inhibitor activity in the cases in which there is a good homolog structure 
with a sufficient degree of sequence resemblance. However, homology models 
usually fail when used for optimizing selectivity since one of the main 
determinants of compound selectivity for a particular target is the degree of 
structural and physicochemical divergence with respect to other potential targets. 
In this regard, it is generally agreed that when building a homology model, there 
is a direct correlation between sequence identity and predicted structure quality, 
being unaligned target sequences particularly prone to deliver substantially less 
accurate structures.195 Accounting for all this, HDAC6 homology models would 
have introduced a significant degree of structural distortion on the 
aforementioned surface cavity since all of them were based on X-ray structures 
of HDAC isoforms with substantial sequence and architectural divergence with 





highlighted the potential importance of the discussed surface area for HDAC6 
inhibitory activity and selectivity.118,119 However, to our knowledge this is the first 
report in which systematic spacer modifications maintaining the same cap 
structure have demonstrated through experimental and computational 
approaches the critical role that cap pre-organization and orientation on the 
protein surface play on HDAC6 selectivity determination. 
Interestingly, all compounds that exhibited some binding affinity for HDAC6 
CD2 in silico were also able to bind HDAC6 CD1 homology model. However, the 
correlation between the predicted binding affinities in CD1 and the in vitro 
deacetylation activity on acetylated α-Tubulin was substantially lower than that 
observed for CD2. This result is in accordance with recent findings demonstrating 
that although catalytically active, CD1 possess a high degree of substrate 
selectivity for other substrates rather than for acetylated α-Tubulin.118 In particular 
it has been pointed out the ability of CD1 to catalyze deacetylation in substrates 
containing C-terminal acetyl lysine residues.119 
Once the affinity and selectivity for HDAC6 inhibition was confirmed in 4 of 
the newly synthesized UDCA-HDAC6i molecules, UDCA-HDAC6i #1 was 
selected for further in vivo analysis based on its predicted pharmacokinetic 
features and synthetic advantages. One of the points of our hypothesis was that 
the new UDCA-HDAC6i molecules could benefit from the intrinsic hepatotropic 
features of UDCA, concentrating them preferentially into the liver and in cystic 
cholangiocytes after oral administration and gastrointestinal absorption. In 
addition, these molecules could also be re-absorbed through the enterohepatic 
circulation. Thus, we applied the QikProp software included in the Maestro 





molecules, obtaining considerably better values for UDCA-HDAC6i #1 than for 
the other three active candidates (including UDCA-HDAC6i #9) in terms of oral 
absorption. UDCA-HDAC6i #1 displayed values within the recommended range 
for all the parameters analyzed except one, whereas UDCA-HDAC6i #2 and #9 
presented several potential limitations. We also hypothesized that the new 
UDCA-HDAC6i molecules could preserve some of the previously reported 
therapeutic features of UDCA for PLD either directly as part of the UDCA-HDAC6i 
molecule or after intestinal metabolism of the amide bond and further liberation 
of an intact UDCA molecule. In this regard, the capacity of UDCA to inhibit cystic 
cholangiocyte proliferation in vitro is within the µM range15 while UDCA-HDAC6is 
display high HDAC6 inhibitory activity and further anti-proliferative effect in the 
nM range. Thus, we attempted to select a candidate that could provide a balance 
in the contribution of both elements to the dual therapeutic effect. Moreover, the 
chemical synthesis of UDCA-HDAC6i #1 is faster and cheaper than others like 
UDCA-HDAC6i #9. Thus, while UDCA-HDAC6i #1 requires only two synthetic 
steps with an overall yield of 51%, UDCA-HDAC6i #9 needs four steps what 
requires more starting materials and leads to a substantial drop in the overall yield 
to only 27%. 
Oral administration of UDCA-HDAC6i #1 to PCK rats considerably reduced 
the hepato- and nephromegaly characteristic on these animals, as well as the 
hepatic cystogenesis. In addition, this new molecule partially normalized the 
decreased serum levels of albumin, suggesting an improvement of liver function 
of these animals. Moreover, the levels of urea in serum were reduced upon 
treatment with the synthetic UDCA derivative, indicating an improvement in renal 





and histological levels. Of note, these therapeutic effects were greater and more 
significant than those observed for UDCA, even using lower doses (i.e., 15 
mg/kg/day for UDCA-HDAC6i #1 versus 25 mg/kg/day for UDCA15 during  5 
months, respectively), as only changes in hepatic cystogenesis were observed 
upon UDCA treatment.15 At the histological level, increased levels of acetylated 
-Tubulin were observed in both liver and kidneys of treated PCK rats compared 
to untreated animals, supporting that UDCA-HDAC6i #1 is properly absorbed in 
the gut and is able to reach and exert its pharmacological effect in these tissues.  
In agreement with these results, UDCA-HDAC6i #1 increased the primary cilium 
length of human cystic cholangiocytes in an acetylated -Tubulin dependent 
manner, whereas it had no effect on the primary cilium length of normal human 
cholangiocytes in vitro. Moreover, UDCA-HDAC6i #1 inhibited the proliferation of 
cystic cholangiocytes cultured in 2D and 3D conditions. Importantly this anti-
proliferative effect was much higher than the one exerted by the combined 
treatment with its pharmacologically active components (i.e., UDCA + chelating 
agent) at the same concentration. This result indicates that the covalent 
combination of these two components into the same chemical entity gives rise to 
a novel therapeutic profile much superior than the simple sum of their individual 
pharmacological effects. This phenomenon was also accompanied by a 
significant reduction in ERK1/2 phosphorylation, one of the main molecular 
pathways involved in mediating cystic cholangiocyte hyperproliferation.6 All these 
data are consistent with the fact that the primary cilium acts as a checkpoint 
inhibitor of the cell cycle, being its restoration in cystic cholangiocytes a novel 





Regarding the bile acid metabolism, and similarly to our previous data with 
UDCA, no significant changes in the total bile acid concentration were observed 
between UDCA-HDAC6i #1-treated and non-treated animals. However, changes 
in certain bile acid species in bile and liver were found. Noteworthy, increased 
levels of free UDCA in liver, bile and serum were found in PCK rats treated with 
UDCA-HDAC6i #1. This result reinforced the idea that biliary UDCA-HDAC6i #1 
could be further metabolized in the gut through the cleavage of the amide bond, 
resulting in the release of free UDCA that may enter the entero-hepatic circulation 
in a second round and induce additional therapeutic effect on hepatic 
cystogenesis.  
As indicated above, two important limitations of currently available HDAC6is 
are their lack of selective affinity towards the hepatic tissue as well as the 
presence of aromatic peptide derivatives and hydrocarbons in their structures,128-
130,187  which can be released as potentially toxic metabolites. Our data reveal 
that oral administration of UDCA-HDAC6i #1 accumulates preferentially in bile, 
rather than in systemic blood, indicating a superior targeting to the liver and 
posterior secretion into bile, thus potentially diminishing the off-target effects in 
peripheral tissues. This preferential biodistribution to the liver could be favored 
by specific transport activities. UDCA-HDAC6i #1 showed specific transport 
thought the bile acid transporter NTCP and the organic cation transporters OCT1 
and OCT3. Although NTCP was found downregulated in cystic cholangiocytes, 
organic cation transporters OCT1 and OCT3 were markedly upregulated in these 
cells compared to normal cholangiocytes. The presence of the UDCA moiety in 
the UDCA-HDAC6i #1 structure may favor its transport through NTCP. These 





cholangiocytes, may suggest a preferential uptake of these new UDCA synthetic 
derivatives to target cystic cholangiocytes. 
In summary, this study has taken advantage of the last discoveries in the 
field of PLDs to develop, through a multidisciplinary approach, a novel therapeutic 
strategy to target several dysregulated molecular mechanisms of pathogenesis  
(i.e., decreased acetylation of -tubulin in the primary cilium, downregulated iCa2+ 
Ievels, increased levels of cytotoxic and pro-mitotic bile acids in the liver) with a 
single chemical entity. UDCA-HDAC6i #1 showed higher therapeutic benefits 
than those of UDCA treatment alone. In addition, this synthetic inhibitor exerted 
superior anti-proliferative effect than the one produced by the combination of its 
two separate molecular components (UDCA and chelating group). These new 
UDCA synthetic conjugates possess high hepatotropism, most probably through 
their uptake via bile acid and cation organic transporter, and are highly 
concentrated into the entero-hepatic circulation. These particular features also 
make the UDCA-HDAC6i molecules especially promising for the treatment of 
other hepatic and gastrointestinal disorders where HDAC6 inhibition is 
considered a target for therapy, such as acute liver failure, cholangiocarcinoma, 
pancreatic cancer or colon cancer, among others,172,198-203 therefore highlighting 
the high degree of translational potential of this new family of molecules. 
Nevertheless, this work has explored through in vitro and in silico approaches 
some structural determinants of HDAC6 inhibitory activity and selectivity, 
providing important novel insights for the understanding of HDAC6 selective 





































I. Four of the newly synthesized UDCA-HDAC6is exert potent and highly 
selective HDAC6 inhibitory activity, while a fifth compound exhibited highly 
selective inhibitory activity towards nuclear HDACs. 
II. UDCA actively contributes to the HDAC6 inhibitory activity of UDCA-
HDAC6is by establishing van der Waals and hydrogen bond interactions 
with residues of the outer cavities of HDAC6 CDs, and this contribution 
can be up to one third of the total binding energy of the compound. 
III. The pre-organization and preferential orientation of UDCA towards a 
particular region of the surface of HDAC6 CD2 is critical to determine 
UDCA-HDAC6i selectivity. 
IV. UDCA-HDAC6i #1 possess the highest degree of translational potential 
based on its potency and selectivity, pharmacokinetic properties and 
synthetic cost. 
V. Upon oral administration, UDCA-HDAC6i #1 preferentially accumulates in 
bile, indicating good targeting capacity towards hepatobiliary system. 
VI. Chronic oral treatment of PCK rats with UDCA-HDAC6i #1 reduced their 
hepato- and nephromegaly, decreased their hepatic cystogenesis and 
improved both hepatic and renal functions in these experimental model of 
PLD. In addition, increased levels of acetylated -tubulin in liver and 
kidneys of treated animals confirmed a direct pharmacological effect on 
these tissues. 
VII. Chronic oral treatment with UDCA-HDAC6i #1 produced significant 





the increase in the concentration of free UDCA observed in the liver, bile 
and serum of the treated animals. 
VIII. The primary cilia of cystic human cholangiocytes is significantly shorter 
than in normal human cholangiocytes. Incubation of cystic human 
cholangiocytes with UDCA-HDAC6i #1 increases the levels of acetylated 
-tubulin in a dose-dependent manner and significantly elongates the 
primary cilia of these cells; these effects were not observed in normal 
human cholangiocytes. 
IX. Incubation of cystic cholangiocytes with UDCA-HDAC6i #1 inhibited the 
hyperproliferation of these cells in 2D and 3D cultures. This anti-
proliferative effect was far superior than the one exerted by the combined 
treatment with its pharmacologically active components. 
X. Incubation of cystic cholangiocytes with UDCA-HDAC6i #1 reduced the 
phosphorylation of ERK1/2, providing further explanation of the molecular 
mechanisms involved in this anti-proliferative effect. 
XI. UDCA-HDAC6i #1 is actively transported through the bile acid transporter 
NTCP and the upregulated organic cation transporters OCT1 and OCT3 
in cystic cholangiocytes. 
 
All together, these findings open a new therapeutic avenue for the treatment of 
PLDs, and can provide useful data for future drug developments either in the field 
































The X-ray structure of the human HDAC6 catalytic domain 2 was obtained from 
RCSB Protein Data Bank (PDB entry 5EDU). The protein structure was optimized 
and minimized using the protein preparation wizard software204 included in 
Maestro 10.4 package (Schrödinger, NY, USA). Ligands were represented with 
Maestro graphic interface and optimized with LigPrep tool included in Maestro 
10.4 package. Flexible docking experiments were carried out using Glide 
software205,206  included in Maestro 10.4 package, using extra precision mode207 
to maximize accuracy of the obtained results. Obtained structures and binding 
predicted energies were analyzed using Maestro and Pymol graphic interfaces. 
 
M.2 Homology modeling 
Homology model of Human HDAC6 CD1 was generated with Prime 
software181,182 included in Maestro 10.4 package. Amino acid sequence of human 
HDAC6 (Uniprot code: Q9UBN7) CD1 comprising residues between 87 and 404 
positions was submitted to secondary structure prediction. Next, predicted 
secondary structure was aligned to that of Danio rerio HDAC6 CD1 (PDB code: 
5G0G) by using ClustalW algorithm. Once aligned both structures, a knowledge-
based model of human HDAC6 CD1 was constructed based on the tertiary 
structure of Danio rerio HDAC6 CD1. Finally, protein loops were refined, and 
protein structure was prepared for docking experiments as explained above. 
 
 




M.3 Chemical synthesis and characterization 




This compound was prepared following the method A described above. 
Ursodeoxycholic acid (393 mg, 1 mmol) methyl 4-(aminomethyl) benzoate 
hydrochloride (202 mg, 1 mmol), TBTU (385 mg, 1.2 mmol), Et3N in DMF (1.1 
mL, 3.26 M). White solid. Yield 84%; m.p.. 114-116 ˚C; IR 3293, 2927, 2862, 
1720, 1650, 1277, 1106 cm-1; 1H NMR (400 MHz, DMSO-d6) δ:  8.39 (t, J = 6.0 
Hz, 1H), 7.90 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H), 4.49 (d, J = 4.4 Hz, 
1H), 4.32 (dd, J = 6.0, 2.7 Hz, 2H), 3.88 (d, J = 6.7 Hz, 1H), 3.83 (s, 3H), 3.29 (s, 
2H), 2.28 – 2.02 (m, 2H), 1.96 – 1.61 (m, 6H), 1.55 – 1.25 (m, 10H), 1.25 – 0.93 
(m, 7H), 0.93 – 0.83 (m, 7H), 0.60 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 
172.77, 166.06, 145.50, 129.16, 128.06, 127.26, 69.77, 69.48, 55.89, 54.77, 
52.01, 43.10, 43.01, 42.22, 41.80, 39.86, 38.78, 37.74, 37.28, 34.93, 34.86, 
33.76, 32.42, 31.67, 30.25, 28.20, 26.71, 23.32, 20.89, 18.44, 12.00; HRMS (ESI) 












This compound was prepared following the method C described above. 
Glycoursodeoxycholic acid (121 mg, 0.27 mmol) methyl 4-(aminomethyl) 
benzoate hydrochloride (54 mg, 0.27) TBTU (104 mg, 0.32 mmol) Et3N (0.3 mL, 
3.26 M). White solid. Yield 63%; m.p. 145-147 ˚C; IR 3354, 2932, 2861, 1720, 
1654, 1281, 1111, 847 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 8.41 (t, J = 6.1 Hz, 
1H), 8.09 (t, J = 5.9 Hz, 1H), 7.90 (d, J = 8.2 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 
4.45 (d, J = 4.5 Hz, 1H), 4.35 (d, J = 6.0 Hz, 2H), 3.87 (d, J = 6.8 Hz, 1H), 3.84 
(s, 3H), 3.71 (d, J = 5.8 Hz, 2H), 3.29 (2H), 2.25 – 1.96 (m, 2H), 1.95 – 1.59 (m, 
5H), 1.55 – 1.25 (m, 9H), 1.25 – 0.93 (m, 7H), 0.93 – 0.85 (m, 7H), 0.60 (s, 3H); 
13C NMR (101 MHz, DMSO-d6) δ 173.14, 169.42, 166.12, 145.21, 129.17, 
128.09, 127.31, 69.75, 69.49, 55.89, 54.79, 52.11, 43.11, 43.04, 42.19, 41.78, 
38.75, 38.28, 37.76, 37.29, 35.02, 34.86, 33.79, 32.21, 31.46, 30.27, 28.22, 
26.76, 23.35, 20.88, 18.53, 12.08. HRMS (ESI) for C28H47NO4 calculated [[M + 
H] + [-H2O]]+: 579.3798. Obtained: 579.3783. 
 








This compound was prepared following the method A described above. 
Ursodeoxycholic acid (393 mg, 1 mmol) L-Alanine methyl ester hydrochloride 
(140 mg, 1 mmol) TBTU (385 mg, 1.2 mmol) and Et3N (1.1 mL, 3.26 M) White 
solid. Yield 45%; m.p. 103-105 ˚C; IR 3296, 2928, 2863, 1739, 1650, 1209, 1049 
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 8.19 (d, J = 7.0 Hz, 1H), 4.44 (d, J = 4.5 
Hz, 1H), 4.23 (p, J = 7.2 Hz, 1H), 3.87 (d, J = 6.8 Hz, 1H), 3.60 (s, 3H), signal 
corresponding to 2H overlapped with broad signal of water at 3.29 ppm 
(confirmed by COSY), 2.19 – 1.88 (m, 3H), 1.88 – 1.57 (m, 4H), 1.56 – 1.27 (m, 
9H), 1.27 – 0.93 (m, 12H), 0.93 – 0.82 (m, 7H), 0.61 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 173.26, 172.52, 69.71, 69.45, 55.87, 54.71, 51.72, 47.41, 43.07, 
43.01, 42.16, 38.71, 37.72, 37.27, 34.87, 34.82, 33.75, 31.94, 31.47, 30.24, 
28.16, 26.71, 23.31, 20.84, 18.47, 16.93, 12.03; HRMS (ESI) for C28H48NO5 












This compound was prepared following the method A described above. 
Ursodeoxycholic acid (393 mg, 1 mmol) β-Alanine ethyl ester hydrochloride (154 
mg, 1 mmol), TBTU (385 mg, 1.2 mmol) Et3N (1.1 mL, 3.26 M). White solid. Yield 
66%; m.p. 84-86 ˚C; IR 3292, 2927, 2862, 1734, 1647, 1180, 1049 cm-1; 1H NMR 
(400 MHz, DMSO-d6) δ 7.85 (t, J = 5.7 Hz, 1H), 4.43 (d, J = 4.6 Hz, 1H), 4.05 (q, 
J = 7.1 Hz, 2H), 3.86 (d, J = 6.8 Hz, 1H), 3.29 (2H),  3.24 (q, J = 6.5 Hz, 2H), 2.41 
(t, J = 6.8 Hz, 2H), 2.12 – 1.89 (m, 4H), 1.89 – 1.59 (m, 4H), 1.53 – 1.25 (m, 9H), 
1.24 – 0.90 (m, 11H), 0.87 (t, J = 3.3 Hz, 7H), 0.61 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 172.63, 171.30, 69.70, 69.45, 59.86, 55.86, 54.69, 43.06, 43.00, 
42.16, 38.71, 37.72, 37.26, 34.90, 34.82, 34.65, 33.90, 33.75, 32.29, 31.60, 
30.24, 28.15, 26.70, 23.31, 20.84, 18.45, 14.08, 12.01; HRMS (ESI) for 












This compound was prepared following the method A described above. 
Ursodeoxycholic acid (393 mg, 1 mmol) 4-aminobutirate methyl ester 
hydrochloride (154 mg, 1 mmol) TBTU (385 mg, 1.2 mmol) Et3N (1.1 mL, 3.26 
M). White solid. Yield 37 %; m.p. 92-94 ˚C; IR 3295, 2927, 2862, 1736, 1646, 
1170, 1050 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 7.77 (t, J = 5.7 Hz, 1H), 4.42 
(d, J = 4.6 Hz, 1H), 3.85 (d, J = 6.8 Hz, 1H), 3.58 (s, 3H), 3.02 (q, J = 6.5 Hz, 2H), 
2.29 (t, J = 7.5 Hz, 2H), 2.15 – 2.00 (m, 1H), 2.01 – 1.53 (m, 9H), 1.54 – 1.24 (m, 
8H), 1.24 – 0.90 (m, 7H), 0.88 (d, J = 7.4 Hz, 7H), 0.60 (s, 3H); 13C NMR (101 
MHz, DMSO-d6) δ 173.04, 172.45, 69.67, 69.41, 55.83, 54.66, 51.20, 43.03, 
42.97, 42.13, 38.68, 37.69, 37.60, 37.23, 34.87, 34.79, 33.72, 32.38, 31.63, 
30.65, 30.21, 28.14, 26.67, 24.52, 23.28, 20.80, 18.42, 11.96;  HRMS (ESI) for 












This compound was prepared following the method A described above. 
Ursodeoxycholic acid (393 mg, 1 mmol), 6-aminohexanoate methyl ester 
hydrochloride (182 mg, 1 mmol) TBTU (385 mg, 1.2 mmol) and Et3N (1.1 mL, 
3.26 M). White solid. Yield 42%; m.p. 78-80 ˚C; IR 3299, 2926, 2861, 1736, 1644, 
1165, 1050 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 7.71 (t, J = 5.7 Hz, 1H), 4.43 
(d, J = 4.5 Hz, 1H), 3.86 (d, J = 6.7 Hz, 1H), 3.58 (s, 3H), 3.29 (2H), 2.99 (q, J = 
7.1 Hz, 2H), 2.28 (t, J = 7.4 Hz, 2H), 2.14 – 1.56 (m, 10H), 1.56 – 0.91 (m, 20H), 
0.88 (d, J = 7.2 Hz, 8H), 0.60 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 173.26, 
172.28, 69.70, 69.45, 55.87, 54.70, 51.15, 43.06, 43.00, 42.16, 38.71, 38.12, 
37.71, 37.26, 34.90, 34.82, 33.75, 33.22, 32.44, 31.69, 30.24, 28.82, 28.16, 
26.70, 25.84, 24.15, 23.30, 20.83, 18.45, 12.00; HRMS (ESI) for C31H54NO5 












This compound was prepared following the method A described above. 
Ursodeoxycholic acid (145 mg, 0.37 mmol), 5-(aminomethyl)furan-2-carboxilato 
methyl ester hydrochloride (71 mg, 0.37) TBTU (146 mg, 0.46 mmol) Et3N (0.41 
mL, 3.26 M). White solid. Yield 52%; m.p. 240-242 ̊ C; IR 3463, 3285, 2935, 1705, 
1683, 1518, 1210, 763 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 8.38 (t, J = 5.8 Hz, 
1H), 7.23 (d, J = 3.5 Hz, 1H), 6.40 (d, J = 3.4 Hz, 1H), 4.42 (d, J = 4.5 Hz, 1H), 
4.29 (d, J = 5.7 Hz, 2H), 3.85 (d, J = 6.8 Hz, 1H), 3.79 (s, 3H), signal 
corresponding to 2H overlapped with broad signal of water at 3.29 ppm 
(confirmed by COSY), 2.09 (m, J = 39.5, 14.2, 7.9 Hz, 2H), 1.96 – 1.58 (m, 5H), 
1.54 – 1.24 (m, 10H), 1.24 – 0.90 (m, 8H), 0.87 (d, J = 6.5 Hz, 7H), 0.58 (s, 3H); 
13C NMR (101 MHz, DMSO-d6) δ 172.63, 158.23, 157.68, 142.62, 119.31, 
109.11, 69.71, 69.45, 55.85, 54.69, 51.65, 43.06, 43.00, 42.16, 39.99, 38.71, 
37.72, 37.27, 35.57, 34.86, 34.82, 33.75, 32.20, 31.54, 30.24, 28.15, 26.70, 
23.30, 20.83, 18.42, 11.99; HRMS (ESI) for C31H51N2O6 calculated [M + NH4]+: 
547.3745. Obtained: 547.3738. 
 




Example 8: Synthesis of 4-(((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-
dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)methyl)benzoic acid. (4a) 
 
 
This compound was prepared following the method B described above. 
4-(((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido) 
methyl) benzoate (1079 mg, 2 mmol), NaOH (8.7 mL, 0.5M). White solid. Yield 
90%; m.p. 155-157 ˚C; IR 3288, 2922, 2851, 1638, 1542, 1281, 1015 cm-1; 1H 
NMR (400 MHz, DMSO-d6) δ 12.85 (s, 1H), 8.37 (t, J = 6.0 Hz, 1H), 7.88 (d, J = 
8.2 Hz, 2H), 7.34 (d, J = 8.1 Hz, 2H), 4.48 – 4.39 (m, 1H), 4.34 – 4.28 (m, 2H), 
3.86 (d, J = 6.8 Hz, 1H), signal corresponding to 2H overlapped with broad signal 
of water at 3.29 ppm, 2.24 – 2.01 (m, 2H), 1.98 – 1.60 (m, 6H), 1.53 – 1.26 (m, 
10H), 1.26 – 0.93 (m, 7H), 0.93 – 0.85 (m, 7H), 0.61 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 172.67, 167.15, 145.01, 129.30, 129.19, 127.10, 69.73, 69.47, 
55.88, 54.76, 43.09, 43.01, 42.18, 41.77, 39.84, 38.74, 37.73, 37.27, 34.89, 
34.83, 33.76, 32.38, 31.65, 30.25, 28.19, 26.72, 23.32, 20.85, 18.44, 12.01; 
HRMS (ESI) para C32H48NO5 calculated [M + H]+: 525.3532. Obtained: 525.3538. 
 









This compound was prepared following the method C described above.  
4-(((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido) 
methyl)benzoic acid (200 mg, 0.38 mmol) methyl 4-(aminomethyl) benzoate 
hydrochloride  (77 mg 0.38 mmol) TBTU (146 mg 0.46 mmol) Et3N (0.42 mL, 3.26 
M). White solid. Yield 60%; m.p.139-141 ˚C; IR 3301, 2926, 2861, 1719, 1638, 
1276, 1107, 1047 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.08 (t, J = 6.0 Hz, 1H), 
8.36 (t, J = 6.0 Hz, 1H), 7.92 (d, J = 8.1 Hz, 2H), 7.85 (d, J = 8.1 Hz, 2H), 7.44 (d, 
J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 4.55 (d, J = 5.9 Hz, 2H), 4.45 (d, J = 4.5 
Hz, 1H), 4.36 – 4.15 (m, 2H), 3.87 (d, J = 6.8 Hz, 1H), 3.83 (s, 3H), 3.29 (2H), 
2.23 – 2.01 (m, 2H), 1.97 – 1.59 (m, 6H), 1.55 – 1.25 (m, 10H), 1.25 – 0.93 (m, 
7H), 0.93 – 0.82 (m, 7H), 0.61 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 172.67, 
166.11, 145.41, 143.37, 132.52, 129.25, 128.10, 127.29, 126.95, 69.73, 69.48, 
55.88, 54.77, 52.06, 43.10, 43.02, 42.40, 42.18, 41.71, 38.73, 37.73, 37.28, 
34.91, 34.84, 33.77, 32.41, 31.68, 30.25, 28.20, 26.73, 23.32, 20.86, 18.46, 
12.04; HRMS (ESI) for C41H57N2O6 calculated [M + H]+: 673.4216. Obtained: 
673.4214. 








methyl)-N-hydroxybenzamide. UDCA-HDAC6i #1: 
 
This compound was prepared following the method A described above. 
Methyl 4-(((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido) 
methyl)benzoate (539 mg, 1 mmol), hydroxylamine hydrochloride  (695 mg, 10 
mmol), phenolphthalein (1 mg), sodium methoxide (2000 mg, 37 mmol). White 
solid. Yield 61 %;  m.p. 170-172 ˚C; IR 3275, 2927, 2862, 1638, 1535, 1012 cm-
1;  1H NMR (400 MHz, DMSO-d6) δ 11.17 (s, 1H), 9.01 (s, 1H), 8.34 (t, J = 6.0 Hz, 
1H), 7.69 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 4.44 (d, J = 4.5 Hz, 1H), 
4.28 (dd, J = 5.9, 3.6 Hz, 2H), 3.87 (d, J = 6.8 Hz, 1H), 3.29 (2H). 2.24 – 2.01 (m, 
2H), 1.99 – 1.59 (m, 6H), 1.56 – 1.26 (m, 10H), 1.26 – 0.94 (m, 7H), 0.94 – 0.84 
(m, 7H), 0.62 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 172.63, 163.99, 143.06, 
131.18, 126.92, 126.83, 69.73, 69.47, 55.88, 54.76, 43.09, 43.02, 42.18, 41.71, 
39.85, 38.73, 37.73, 37.27, 34.93, 34.84, 33.77, 32.38, 31.67, 30.25, 28.21, 
26.73, 23.33, 20.86, 18.44, 12.04; HRMS (ESI) for C32H47N2O4 calculated [[M + 
H] + [-H2O]]+: 523.3536. Obtained: 523.3536. 
 






pentanamido)acetamido)methyl)-N-hydroxybenzamide. UDCA-HDAC6i #2 
 
This compound was prepared following the method C described above. 
Methyl 4-((2-((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido) 
acetamido)methyl)benzoate (84 mg, 0.14 mmol), hydroxylamine hydrochloride  
(97 mg, 1.4 mmol), phenolphthalein (1 mg), sodium methoxide (2000 mg, 37 
mmol). White solid. Yield 42% m.p. 153-155 ̊ C; IR 3217, 2928, 2864, 1641, 1534, 
1013 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 11.17 (s, 1H), 8.98 (s, 1H), 8.35 (t, J 
= 6.0 Hz, 1H), 8.05 (t, J = 5.9 Hz, 1H), 7.69 (d, J = 8.1 Hz, 2H), 7.30 (d, J = 8.0 
Hz, 2H), 4.46 – 4.40 (m, 1H), 4.31 (d, J = 6.0 Hz, 2H), 3.86 (d, J = 6.7 Hz, 1H), 
3.71 (d, J = 5.9 Hz, 2H), 3.29  (2H) , 2.11 (m, J = 57.0, 14.2, 10.0, 5.6 Hz, 2H), 
1.97 – 1.89 (m, 1H), 1.90 – 1.58 (m, 5H), 1.54 – 1.25 (m, 10H), 1.25 – 0.93 (m, 
7H), 0.93 – 0.83 (m, 7H), 0.61 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 173.04, 
169.24, 164.03, 142.70, 131.21, 126.94, 126.81, 69.71, 69.46, 55.87, 54.73, 
43.07, 43.01, 42.17, 42.10, 41.71, 38.72, 37.72, 37.27, 34.98, 34.83, 33.76, 
32.18, 31.42, 30.25, 28.18, 26.72, 23.31, 20.85, 18.51, 12.05; HRMS (ESI) for 
C34H52N3O6 calculated [M + H]+: 598.3856. Obtained: 598.3857. 
 






(hydroxyamino)-1-oxopropan-2-yl) pentanamide. UDCA-HDAC6i #3 
 
This compound was prepared following the method A described above. 
Methyl ((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-L-
alaninate (193 mg, 0.4 mmol), hydroxylamine hydrochloride  (278 mg, 4 mmol), 
phenolphthalein (1 mg), sodium methoxide (2000 mg, 37 mmol).White solid. Yield 
22%. m.p. 170-172 ˚C; IR 3265, 2928, 2863, 1642, 1537, 1047 cm-1; 1H NMR 
(400 MHz, DMSO-d6) δ 7.96 (d, J = 7.8 Hz, 1H), 4.44 (s, 1H), 4.17 (p, J = 7.1 Hz, 
1H), 3.86 (d, J = 6.6 Hz, 1H),3.29 (2H) ), 2.13 (m, J = 14.8, 10.2, 5.2 Hz, 1H), 
2.04 – 1.89 (m, 2H), 1.89 – 1.55 (m, 4H), 1.54 – 1.24 (m, 10H), 1.22 – 0.93 (m, 
11H), 0.88 (d, J = 6.1 Hz, 7H), 0.61 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 
172.19, 169.09, 69.71, 69.45, 55.87, 54.71, 45.74, 43.07, 43.01, 42.16, 38.72, 
37.72, 37.26, 35.03, 34.83, 33.75, 32.10, 31.48, 30.24, 28.18, 26.72, 23.31, 











(hydroxyamino)-3-oxopropyl)pentanamide. UDCA-HDAC6i #4 
 
This compound was prepared following the method A described above. 
Ethyl 3-((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido) 
propanoate (298 mg, 0.61 mmol), hydroxylamine hydrochloride  (424 mg, 6.1 
mmol), phenolphthalein (1 mg), sodium methoxide (2000 mg, 37 mmol). White 
solid. Yield 59%; m.p. 180-182 ˚C; IR 3271, 2927, 2862, 1638, 1542, 1047 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 7.82 (t, J = 5.7 Hz, 1H), 4.43 (s, 1H), 3.86 (d, J 
= 6.8 Hz, 1H), 3.30 (s, 2H), 3.19 (q, J = 6.8 Hz, 2H), 2.11 (m, 2H), 1.99 – 1.56 (m, 
8H), 1.54 – 1.24 (m, 8H), 1.23 – 0.90 (m, 9H), 0.87 (d, J = 4.4 Hz, 7H), 0.61 (s, 
3H); 13C NMR (101 MHz, DMSO-d6) δ 172.53, 167.03, 69.71, 69.45, 55.86, 54.70, 
43.07, 43.01, 42.16, 39.99, 38.71, 37.72, 37.27, 35.27, 34.98, 34.83, 33.75, 
32.53, 32.35, 31.59, 30.24, 28.17, 26.71, 23.31, 20.84, 18.47, 12.04; HRMS (ESI) 










(hydroxyamino)-4-oxobutyl)pentanamide. UDCA-HDAC6i #5 
 
This compound was prepared following the method A described above. 
Methyl 4-((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido) 
butanoate (165 mg, 0.34 mmol), hydroxylamine hydrochloride (237 mg, 3.4 
mmol), phenolphthalein (1 mg), sodium methoxide (2000 mg, 37 mmol). White 
solid. Yield 54%. m.p. 165-167 ˚C; IR 3269, 2928, 2862, 1643, 1550, 1047 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 7.81 (t, J = 5.6 Hz, 1H), 4.46 (s, 1H), 3.88 (d, J 
= 6.6 Hz, 1H), señal correspondiente a 2H superpuesta con señal de agua a 3.29 
ppm (confirmado por COSY), 3.00 (q, J = 6.6 Hz, 2H), 2.16 – 1.91 (m, 6H), 1.89 
– 1.54 (m, 7H), 1.54 – 1.25 (m, 9H), 1.25 – 0.92 (m, 9H), 0.89 (d, J = 7.8 Hz, 7H), 
0.62 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 172.45, 168.69, 69.71, 69.45, 
55.87, 54.70, 43.07, 43.01, 42.17, 38.72, 38.05, 37.72, 37.27, 34.97, 34.83, 
33.76, 32.43, 31.67, 30.24, 29.91, 28.18, 26.72, 25.45, 23.31, 20.84, 18.48, 












This compound was prepared following the method A described above. 
Methyl 6-((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)hexanoate (200 mg, 0.38 mmol), hydroxylamine hydrochloride  
(263, 3.8 mmol), phenolphthalein (1 mg), sodium methoxide (2000 mg, 37 mmol). 
White solid. Yield 43%; m.p. 125-127 ˚C; IR 3269, 2927, 2861, 1642, 1547, 1047 
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 8.64 (s, 1H), 7.71 (t, J = 5.6 
Hz, 1H), 4.43 (d, J = 4.5 Hz, 1H), 3.86 (d, J = 6.8 Hz, 1H),3.29 (2H) ), 2.98 (q, J 
= 6.5 Hz, 2H), 2.06 (m, J = 14.5, 9.7, 5.2 Hz, 1H), 2.00 – 1.53 (m, 9H), 1.55 – 
1.26 (m, 14H), 1.26 – 0.90 (m, 9H), 0.88 (d, J = 7.3 Hz, 7H), 0.61 (s, 3H); 13C 
NMR (101 MHz, DMSO-d6) δ 172.28, 168.99, 69.71, 69.45, 55.87, 54.70, 43.07, 
43.00, 42.16, 38.72, 38.27, 37.72, 37.26, 34.93, 34.82, 33.75, 32.43, 32.20, 
31.69, 30.24, 28.93, 28.18, 26.71, 26.04, 24.88, 23.31, 20.84, 18.47, 12.02; 
HRMS (ESI) for C30H53N2O5 calculated [M + H]+: 521.3954. Obtained: 521.3955. 
 
 









This compound was prepared following the method B described above. 
Tert-butyl (3-(4-(((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)methyl) benzamido)-[1,1'-biphenyl]-4-yl)carbamate (53 mg, 0.07 
mmol) HCl 4M in dioxane (0.3 mL). White solid. Yield 22%; m.p. 163-165 ˚C; IR 
3321, 2927, 2862, 1649, 1489, 1048, 760, 698 cm-1; 1H NMR (400 MHz, DMSO-
d6) δ 9.70 (s, 1H), 8.39 (t, J = 6.0 Hz, 1H), 7.95 (d, J = 7.9 Hz, 2H), 7.59 – 7.49 
(m, 3H), 7.45 – 7.29 (m, 5H), 7.25 (q, J = 7.3, 6.6 Hz, 1H), 6.87 (d, J = 8.3 Hz, 
1H), 5.08 (s, 2H), 4.43 (d, J = 4.6 Hz, 1H), 4.33 (dd, J = 5.9, 3.8 Hz, 2H), 3.86 (d, 
J = 6.8 Hz, 1H), signal corresponding to 2H overlapped with broad signal of water 
at 3.29 ppm, 2.29 – 1.88 (m, 3H), 1.89 – 1.59 (m, 6H), 1.54 – 1.26 (m, 10H), 1.26 
– 0.97 (m, 4H), 0.97 – 0.83 (m, 9H), 0.62 (s, 3H); 13C NMR (101 MHz, DMSO-d6) 
δ 172.66, 165.23, 143.46, 142.74, 140.17, 132.98, 128.78, 128.13, 127.81, 
126.83, 126.00, 125.49, 124.75, 124.65, 123.60, 116.52, 69.71, 69.46, 55.88, 
54.75, 43.09, 43.01, 42.16, 41.73, 38.72, 37.72, 37.27, 34.93, 34.83, 33.76, 
32.41, 31.70, 30.24, 28.20, 26.73, 23.31, 20.85, 18.46, 12.04; HRMS (ESI) for 
C44H58N3O4 calculated [M + H]+: 692.4427. Obtained: 692.4414. 








This compound was prepared following the method B described above. 
4-(((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)methyl) benzoic acid (200 mg, 0.38 mmol) o-Phenylenediamine  
(41 mg, 0.38 mmol) TBTU (146 mg, 0.46 mmol) Et3N (0.42 mL, 3.26 M). White 
solid. Yield 39 %; m.p. 168-170 ˚C; IR 3294, 2927, 2862, 1647, 1505, 1048, 745 
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.61 (s, 1H), 8.38 (t, J = 6.0 Hz, 1H), 7.92 
(d, J = 7.9 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 7.16 (d, J = 7.9 Hz, 1H), 7.04 – 6.92 
(m, 1H), 6.78 (dd, J = 8.0, 1.4 Hz, 1H), 6.69 – 6.49 (m, 1H), 4.88 (s, 2H), 4.42 (d, 
J = 4.6 Hz, 1H), 4.37 – 4.25 (m, 2H), 3.86 (d, J = 6.8 Hz, 1H),  3.29 (2H), 2.25 – 
2.01 (m, 2H), 1.98 – 1.58 (m, 6H), 1.56 – 1.27 (m, 9H), 1.27 – 0.94 (m, 5H), 0.94 
– 0.82 (m, 10H), 0.62 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 172.63, 165.05, 
143.38, 143.11, 132.99, 127.74, 126.81, 126.66, 126.43, 123.32, 116.23, 116.11, 
69.70, 69.46, 55.87, 54.75, 43.08, 43.01, 42.15, 41.71, 38.71, 37.71, 37.26, 
34.91, 34.82, 33.75, 32.39, 31.69, 30.24, 28.19, 26.72, 23.31, 20.84, 18.45, 














This compound was prepared following the method C described above.  
Methyl 4-((4-(((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)methyl) benzamido)methyl)benzoate (134 mg, 0.2 mmol), 
hydroxylamine hydrochloride  (139 mg, 2 mmol), phenolphthalein (1 mg), sodium 
methoxide (2000 mg, 37 mmol). White solid. Yield 60 %; m.p. 187-189 ˚C; IR 
3288, 2922, 2851, 1638, 1542, 1015 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.03 
(t, J = 6.0 Hz, 1H), 8.35 (t, J = 6.0 Hz, 1H), 7.84 (d, J = 8.0 Hz, 2H), 7.70 (d, J = 
7.9 Hz, 2H), 7.33 (dd, J = 10.4, 8.0 Hz, 4H), 4.50 (d, J = 5.9 Hz, 2H), 4.46 – 4.40 
(m, 1H), 4.36 – 4.22 (m, 2H), 3.88 (s, 1H), 3.92 (2H) , 2.28 – 1.99 (m, 2H), 1.99 
– 1.56 (m, 5H), 1.54 – 1.25 (m, 9H), 1.25 – 0.94 (m, 8H), 0.94 – 0.84 (m, 8H), 
0.61 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 172.63, 166.03, 164.08, 143.29, 
142.96, 132.60, 131.26, 127.24, 126.99, 126.90, 69.71, 69.46, 55.86, 54.74, 
43.08, 43.01, 42.35, 42.16, 41.69, 39.99, 38.71, 37.71, 37.27, 34.91, 34.82, 
33.76, 32.38, 31.66, 30.24, 28.18, 26.72, 23.31, 20.84, 18.45, 12.03; HRMS (ESI) 
for C40H54N3O5 calculated [[M + H] + [-H2O]]+: 656.4064. Obtained: 656.4054. 








This compound was prepared following the method A described above.  
Methyl 5-(((4R)-4-((3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido) 
methyl) furan-2-carboxylate (79 mg, 0.15 mmol), hydroxylamine hydrochloride  
(104 mg, 1.5 mmol), phenolphthalein (1 mg), sodium methoxide (2000 mg, 37 
mmol). White solid. Yield 47%; m.p. 149-151 ˚C; IR 3272, 2929, 2864, 1644, 
1540, 1016 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 11.02 (s, 1H), 9.05 (s, 1H), 
8.30 (t, J = 5.6 Hz, 1H), 6.95 (d, J = 3.3 Hz, 1H), 6.30 (d, J = 3.4 Hz, 1H), 4.43 (d, 
J = 4.6 Hz, 1H), 4.26 (d, J = 5.5 Hz, 2H), 3.86 (d, J = 6.8 Hz, 1H), 3.26 (d, J = 5.2 
Hz, 0H), 2.24 – 1.97 (m, 2H), 1.97 – 1.56 (m, 6H), 1.56 – 1.25 (m, 9H), 1.25 – 
0.93 (m, 7H), 0.93 – 0.83 (m, 8H), 0.60 (s, 3H).; 13C NMR (101 MHz, DMSO-d6) 
δ 172.57, 156.39, 154.91, 144.99, 113.56, 108.14, 69.71, 69.45, 55.86, 54.69, 
43.07, 43.01, 42.16, 38.71, 37.72, 37.27, 35.62, 34.93, 34.83, 33.76, 32.18, 
31.52, 30.24, 28.16, 26.71, 23.31, 20.84, 18.45, 12.03; HRMS (ESI) for 
C30H45N2O5 calculated [[M + H] + [-H2O]]+: 513.3329. Obtained: 513.3327. 
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M.4 HDAC activity assays 
The HDAC activity assays were performed using acetylated peptide substrates 
labeled with 7-amino-4-methylcoumarin (AMC) at Reaction Biology Corporation 
(Pennsylvania, USA). All the enzymes and substrates used in the assays are 
summarized in Table M1.  All assays were performed in a solution buffer (50 mM 
Tris-HCl, pH 8.0; 137 mM NaCl; 2.7 mM KCl; 1 mM MgCl2; supplemented with 1 
mg/mL of BSA for dilution; BioMol Cat. # KI-143).  
Briefly, 50 μL of peptide substrate and an optimal concentration of the 
corresponding enzyme (Table M1) were incubated in the assay buffer at a final 
DMSO concentration of 1% in the presence of increased concentrations of 
inhibitors at 30°C for 2 hours. The reactions were carried out in 96-well fluorimeter 
microplates in a final reaction volume of 50 μL. After the deacetylation reaction, 
Fluor-de-Lys-Developer (BioMol Cat. # KI-105) was added to each well to digest 
the deacetylated substrate according to manufacturer instructions, thereby 
producing the fluorescent signal. The reaction was carried out for 45 min at 30°C 
with 5% CO2. Then, the fluorescence signal was measured using an excitation 
wavelength of 360 nm and an emission wavelength at 460 nm in a fluorimeter 
(GeminiXS, Molecular Devices, Sunnyvale, CA). All the experiments were 
performed in triplicate. The IC50 values were calculated by fitting the 
experimental data with Graphpad Prism 6 software using the equation 
log(inhibitor) vs. normalized response with variable slope. DMSO was used as a 
negative control; Trichostatin A (Biomol Cat. # GR-309) was used as a positive 
control inhibitor. 
 


































































M.5 Treatment of PCK rats with HDAC6i-UDCA #1 
 
The PCK rat (Charles River Laboratory, USA) is an animal model of ARPKD, 
presenting a mutation in the human orthologue Pkhd1 gene and spontaneously 
developing both hepatic and renal cystogenesis. All animals used for this 
experiment were male rats. Both wild-type (WT) (n=12) and PCK rats (n=20) were 
8 weeks-old by the beginning of the experiment. PCK rats were randomized into 
HDAC6i-UDCA #1 treated (n=8; 15 mg/kg/day by oral gavage for 5 months) and 
non-treated (n=12) groups. Animal randomization of PCK rats into experimental 
groups was performed based on animal weight as well as different biochemical 
serum parameters such as transaminase levels (ALT, ALP and AST), urea 
concentration, total blood protein and albumin concentrations, confirming no 
significant differences between groups were observed for any of the mentioned 
parameters at the beginning of the experiment. After 5 months treatment, animals 
were sacrificed and systemic blood, portal blood and bile were collected to 
determine BA content and UDCA-HDAC6i #1 concentration. Liver and kidneys 
were collected, weighted and either fixed in 4% paraformaldehyde (PFA) and 
embedded in paraffin, or stored at -80ºC for further analysis. 
 
M.6 Liver histological analysis 
M.6.1 Tissue slides hydration 
For histological analysis, 4-5 µm tissue slides were cut from the paraffin-
embedded liver tissues using a HM355S microtome (Thermo fisher scientific). 
Slides were heated for 30 minutes at 60°C and washed in xylene three times to 




remove paraffin. Next, slides were immersed for 2 minutes in subsequent 
solutions of decreasing ethanol concentrations (100%, 96%, 70% and 50%) and 
washed in phosphate buffered saline (PBS) 1X. 
M.6.2 Haematoxylin and eosin (H&E) staining 
Tissue slides prepared in the previous step were incubated for 15 minutes at 
room temperature with Harris Haematoxylin (Merck), washed with distilled water, 
and placed in a 70% ethanol + 1 % HCl solution for 5 minutes. Next, slides were 
stained with eosin (Merck) for 5 minutes at room temperature. After washing with 
distilled water, slides were dehydrated by subsequent immersions of 2 minutes 
in solutions of increasing ethanol concentrations (50%, 70%, and 100%) and 
incubated twice in xylene for 5 minutes. Finally stained slides were mounted using 
Pertex (Sigma Aldrich). 
M.6.3 CK19 Immunohistochemistry 
Hydrated tissue slides were treated with a solution of 3% hydrogen peroxide in 
methanol for 15 minutes. Next step consisted in antigen retrieval and subsequent 
blocking with Avidin/Biotin blocking kit (Vector laboratories). CK19 primary 
antibody (ARP 03-61029) 1:50 was added and incubated overnight at 4°C. After 
washing with PBS 1X biotinylated secondary antibody was added an incubated 
at room temperature. For results development Vectastain ABC Reagent (Vector 
laboratories) followed by 3,3-diaminobenzidine (DAB) peroxidase substrate Kit 
(Vector laboratories) were used. Finally, Harris Haematoxylin (Merck) was used 
for counterstaining and slides were dehydrated and mounted for microscopic 
analysis 
 




M.7 Bile acid measurement 
The concentration of BA species in liver, bile, peripheral and portal blood was 
measured after methanol precipitation/extraction by HPLC-MS/MS using a 
modification208 of a previously described method.209 These experiments were 
performed by the group of Prof. José J. G. Marin at the University of Salamanca. 
 
M.8 Cell lines and culture conditions 
Primary cultures of normal and cystic human cholangiocytes, previously isolated 
and characterized by our group,17 were seeded at the required cell density for 
each experimental condition on collagen type I coated plates at 0.05mg/mL 
(Corning, NY, USA) in complete media, Dulbecco's Modified Eagle Medium/F12 
(DMEM/F12 1% (Gibco-Invitrogen), fetal bovine serum (FBS) 5% (Gibco-
Invitrogen), MEM-non-essential amino acids 1% (Lonza), Lipid mixture 1% 
(Sigma-Aldrich), MEM vitamin solution 1% (Gibco-Invitrogen), 
Penicillin/Streptomycin 1% (Gibco-Invitrogen), Soyben Trypsin Inhibitor 0.05 
mg/mL (Gibco-Invitrogen), Insulin Transferrin Selenium 1% (Gibco-Invitrogen), 
Bovine Pituitary Extract 30 µg/mL  (Gibco-Invitrogen), Dexamethasone 393 
ng/mL (Sigma-Aldrich), T3 (3, 3' 5-triiodo-L-thyronine) 3.4 µg/mL (Sigma-Aldrich), 
Epidermal Growth Factor (EGF) 25 ng/mL (Gibco-Invitrogen), Forskolin 4.11 
mg/mL (Ascent-Scientific). For transport assays, HepG2 (human 
hepatoblastoma) and CHO-K1 (Chinese hamster ovary) cells were obtained from 
the American Type Culture Collection (LGC Standards, Barcelona, Spain). All cell 
lines were cultured as recommended by the suppliers. 
 




M.9 Experimental overexpression of human transporters in cells 
These experiments were performed by the group of Prof. José J. G. Marin at the 
University of Salamanca. The open reading frame (ORF) of Na+-taurocholate 
cotransporting polypeptide (NTCP, SLC10A1 gene) and organic cation 
transporter 3 (OCT3, SLC22A3) were amplified from total RNA isolated from 
human liver by RT followed by high-fidelity PCR using AccuPrime Pfx DNA 
polymerase (Life Technologies) and specific primers (Table M2). cDNAs were 
cloned into a pWPI lentiviral vector to obtain transfer vectors encoding both 
transporters and eGFP as a reporter gene. Using pWPI plasmid, “empty viruses” 
were generated and used as a negative control. Lentiviral vectors were produced 
in HEK293T cells and used to transduce target CHO cells as described.210 
Monoclonal cells stably expressing each transporter were selected by double 
subcloning using the limiting dilution method. HepG2 cells overexpressing the 
organic cation transporter 1 (OCT1, SLC22A1) were obtained in the same 
manner.211 
Table M2. Oligonucleotide sequence of primers used to clone the ORF of human transporters . 
At the 5’-end of the primers an adapter was added containing the sequence of a restriction site 
for the enzymes MluI (Forward) and SpeI (Reverse). 
 
 




M.10 Transport assays 
These experiments were performed by the group of Prof. José J. G. Marin at the 
University of Salamanca. Cells were seeded onto 24-well plates at 
subconfluence. After 24 hours, cells were incubated with “uptake” medium (96 
mM NaCl, 5.3 mM KCl, 1.1 mM KH2PO4, 0.8 mM MgSO4, 1.8 mM CaCl2, 11 mM 
glucose, and 50 mM HEPES/Tris, pH 7.40) containing 100 M UDCA-HDAC6i #1 
for 1 hour at 37°C. Quinine (OCT1 and OCT3), and taurocholic acid (NTCP) were 
used as inhibitors or competitors.  Transport fluxes were stopped by rinsing the 
cultures 4 times with 1 mL of ice-cold medium, and then, cells were lysed using 
pure water. UDCA-HDAC6i #1 concentration was determined by high 
performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) 
(6410 Triple Quad LC/MS, Agilent Technologies, Santa Clara, CA). 
Chromatographic separation was carried out in isocratic mode in a Zorbax 
Eclipse XDB-C18 column (30 mm x 2.1 mm, 3.5 μm) and kept at 35°C. Flow rate 
was 300 μL/min and mobile phase was 64:36 methanol/water, both containing 5 
mM ammonium acetate and 0.1% formic acid. Electrospray ionization (ESI) in 
negative mode was used, with the following conditions: gas temperature 350°C, 
gas flow 8 L/min, nebulizer 30 psi, capillary voltage 2500 V. MS/MS acquisition 
was performed in multiple reaction monitoring (MRM) mode using the specific 
m/z transitions 539.4-539.4 m/z for UDCA-HDAC6i #1, and 498.4-80.2 m/z for 








M.11 Reverse transcription quantitative polymerase chain reaction (RT-
qPCR) 
M.11.1 RNA extraction 
For RNA extraction, 1 mL TriReagent (Sigma, Misuri, USA) was added to each 
cell culture of human cholangiocytes placed in a 6 well plate. Lysates were 
collected and placed into 1.5 mL Eppendorf tubes. Next, 200 µL of chloroform 
were added to each tube and after 20 seconds vortexing, samples were left for 
10 minutes at room temperature. Following this, samples were centrifuged for 15 
minutes at 14,500 rpm and 4ºC and the aqueous phases (upper part) were 
transferred to clean 1,5 mL tubes. Next, 0.5 mL isopropanol were added to each 
tube and after mixing samples were left for 10 minutes at room temperature and 
further centrifuged at previously mentioned conditions. Liquid phase was 
discarded and 1 mL of a 75% solution of ethanol was added. Samples were 
vortexed and centrifuged at 14,500 rpm and 4ºC for 5 minutes. Finally, after 
discarding the supernatant pellets were left to dry and resuspended in 20 µL 
UltrapureTM DNase/RNase-free distilled water (Invitrogen). RNA concentration 
and purity were measured in a NanoDrop® ND-1000 equipment (Thermo 
Scientific). 
M.11.2 Reverse transcription 
Volume of the samples prepared in the previous step containing 1 µg of RNA was 
diluted to with UltrapureTM of DNase/RNase-free distilled water to a final volume 
of 15 µL. Subsequently 5 µL of a mixture containing 4 μL of iScript mix and 1 μL 
of iScript RT (iScriptTM cDNA Synthesis Kit (Bio-Rad)) was added to each 




sample and reaction was carried out at 25°C for 5 minutes, 42ºC for 30 minutes, 
85°C for 5 minutes in a Veriti™ Thermal Cycler (Applied Biosystems). 
M.11.3 Quantitative real time polymerase chain reaction (qPCR) 
The expression levels of particular genes were measured by qPCR using iQ™ 
SYBR® Green Supermix (Bio-Rad) in a CFX96 Touch apparatus (BioRad). 
RPL22 gene was used as a normalizing control. All the primer sequences are 
summarized in Table M3. 
 
 
Table M3. Oligonucleotide sequence of primers used for qPCR. 
 
M.12 Immunoblotting 
M.12.1 Protein extraction 
Protein extracts were obtained from cell lysates or frozen tissue homogenized 
with RIPA buffer containing 150 mM NaCl, 50 mM Tris pH 7.5, 0.1% sodium 
dodecyl sulfate (SDS), 1% triton X100, 0.5% sodium deoxycholate, protease 
inhibitors (Complete; Roche) and phosphatase inhibitors (1 mM ortovanadate, 10 
mM NaF, 100 mM β-glycerophosphate). 




M.12.2 Protein quantification 
Sample protein concentration was determined by spectrophotometry using 
Pierce Bicinchoninic kit (Thermo fisher Scientific). Appropriate sample dilutions 
as well as BSA standards were prepared in distilled water and 25 µL of each was 
loaded into a 96 well transparent plate. Parallel, a mixture 1:50 of A and B 
reagents was prepared, and 200 µL of this was added to each well. Finally, plate 
was incubated at 37°C for 30 minutes and measured at a wavelength of 570 nm 
in a Multiskan Ascent® spectrophotometer (Thermo fisher Scientific). 
 
M.12.3 Protein expression or post-translational modification analysis 
Protein expression, acetylation and phosphorylation levels were measured by 
immunoblotting using either 30 µg of cell culture protein extract or 40 µg of PCK 
rat liver or kidney tissue. Samples were separated by electrophoresis in 10% 
SDS-PAGE acrylamide gels and electro-transferred onto nitrocellulose 
membranes (BioRad, Hercules, CA). After blocking with either 2.5% BSA or 2.5% 
skimmed milk powder, membranes were incubated overnight with primary 
antibodies (Table M4). Membranes were then washed with TBS (1% Tween 20) 
and incubated for 1 hour at room temperature with Horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling, 1:5,000). Afterwards, 
membranes were washed with TBS to remove unbound secondary antibody, 
incubated with Novex® ECL HRP Chemiluminescent Substrate Reagent Kit 
(Invitrogen) and visualized in an iBright Imaging System (Thermo Fisher 
Scientific). To determine relative expression or post-translational modification 




levels, obtained images were analyzed with ImageJ software (NIH, Bethesda, 
MD, https://imagej.nih.gov/ij/).213 
 
Table M4. Antibodies used for immunoblot. 
 
M.13 Ciliary length analysis 
These experiments were performed by the group of Dr. Sergio Gradilone at the 
University of Minnesota (Austin, MN, United States). Cholangiocyte cultures in 
glass cover slips were washed and fixed with ice cold (-20ºC) methanol for 10 
minutes. Cells were blocked at room temperature for 1 hour, as previously 
described,172 and incubated overnight at 4°C with acetylated α-tubulin antibodies 
(1:1000; Sigma-Aldrich). Afterwards, cells were incubated for 2 hours at room 
temperature with Alexa Fluor 488 secondary antibody (Life Technologies, USA). 
Next, coverslips were mounted on slides using Prolong Gold Antifade with Dapi 
(Invitrogen; Carlsbad, CA, USA). Images were obtained at 60X with a laser 
scanning confocal microscopy (NIKON C1si Confocal Spectral Imaging System, 
NIKON Instruments Co., Melville, NY, USA), and the fields were zoomed 4X. 




Scale bars were added with EZ-C1 3.90 Freeviewer. Finally, images were 
analyzed for individual cilia length using ImageJ software.213 
 
M.14 Cell proliferation 
Cystic cholangiocytes in culture were stained with CellTrace™ CFSE Cell 
Proliferation Kit (Invitrogen) according to manufacturer’s protocol and seeded 
them at a density of 3x104 cells/well in complete media under collagen type I 
coated 12-well plates. After overnight incubation at 37°C and 5% CO2, cells were 
incubated with 10 µM or 100 µM UDCA, 2 µM or 10 µM UDCA-HDAC6i #1, 10 
µM chelating component, or 10 µM UDCA together with 10 µM chelating 
component in complete media (0.1% DMSO) and were maintained for 48 hours 
at appropriate incubation conditions. Finally, cells were trypsinized and 
fluorescence intensities of individual cells were measured by flow cytometry using 
a Guava® easyCyte 8HT (Merck Millipore). Cell population was gated by size 
and complexity using forward and side scattering. Fluorescence threshold was 
stablished at the fluorescence value in which 50% of control cells were above the 
threshold and 50% of control cells were below the threshold. Proliferation rates 
were calculated by measuring the proportion of cells bellow the fluorescence 
threshold for each condition. 
 
M.15 3D culturing 
Biliary cysts directly isolated from PCK rats were 3D-cultured within a collagen 
type I matrix of 1.8 mg/mL derived from rat tail (Corning, NY, USA) and incubated 




under appropriate culture conditions, as previously reported.214 The cyst growth 
was monitored in HDAC6i-UDCA #1 treated and control groups for 48 hours by 
the acquisition of images every 24 hours. Circumferential areas were measured 
with ImageJ software (NIH, Bethesda, MD).213 
 
M.16 Statistical analysis 
GraphPad Prism 6 was applied for statistical analysis (GraphPad Software). Data 
are expressed as mean ± standard error of the mean (SEM). Unless otherwise 
indicated, for comparisons between two groups, parametric t-Student test or non-
parametric Mann-Whitney test were used. Statistically significant data 

























SUMMARY IN SPANISH 










Las enfermedades hepáticas poliquísticas (PLDs) son un grupo heterogéneo de 
trastornos genéticos hereditarios caracterizados por la dilatación de los 
conductos biliares y/o el desarrollo de múltiples (>10) quistes biliares que 
contienen fluido quístico. Los síntomas más frecuentes relacionados con estas 
patologías son distensión y dolor abdominal, así como saciedad temprana tras 
la ingesta alimenticia. Estos síntomas se originan a partir de distintas 
manifestaciones hepáticas como hepatomegalia, obstrucción biliar y portal, así 
como ruptura y/o infección de los quistes. La enfermedad hepática poliquística 
autosómica dominante (ADPLD, prevalencia  de ~ 1:100.000) se caracteriza por 
el desarrollo de quistes exclusivamente en el hígado, que son la principal causa 
de morbilidad, mientras que la enfermedad renal poliquística autosómica 
dominante (ADPKD, prevalencia  de ~ 1:1.000) y la enfermedad renal poliquística 
autosómica recesiva (ARPKD, prevalencia de ~ 1:20.000) también presentan 
cistogénesis renal, lo que puede conducir a hipertensión y, en última instancia, a 
enfermedad renal terminal.  
Actualmente se cree que los quistes hepáticos se originan a partir de 
defectos embriológicos durante la formación de la placa ductal y/o como 
resultado de mutaciones somáticas en la etapa adulta del individuo. En ese 
sentido, hasta la fecha, se han descrito mutaciones en nueve genes distintos, las 
cuales se encuentran relacionadas con el desarrollo y la progresión de las PLDs 
(ver Tabla I1). Dichas mutaciones dan lugar a distintas alteraciones funcionales 
en los colangiocitos directamente asociadas al aumento de los niveles de 
monofosfato cíclico de adenosina (AMPc) y disminución de la concentración de 




fenómenos como hiperproliferación, hipersecreción, aumento de la actividad 
metaloproteolítica de la matriz extracelular, cambios en la expresión de 
microARNs y alteraciones morfológicas y funcionales del cilio primario, siendo 
estas las principales responsables de la fisiopatología de las PLDs. 
Las terapias actuales frente a las PLDs incluyen una serie de 
procedimientos quirúrgicos, así como estrategias farmacológicas basadas en el 
uso de análogos de somatostatina. Todos estos tratamientos van dirigidos a 
paliar la sintomatología mediante una reducción parcial de las manifestaciones 
hepáticas de la enfermedad. Sin embargo, estas terapias muestran beneficios 
modestos y de escasa duración, así como algunos efectos secundarios, por lo 
que su aplicación se reduce a casos particulares en los cuales la sintomatología 
compromete de manera significativa la calidad de vida del paciente. En ese 
sentido, actualmente el trasplante hepático continúa siendo la única opción 
curativa. Sin embargo, además de que su aplicación conlleva los problemas 
comúnmente asociados al trasplante de órganos, su disponibilidad se ve 
altamente limitada por la naturaleza no letal de las PLDs. Todo ello pone de 
manifiesto la urgente necesidad de desarrollar nuevas terapias que resulten más 
efectivas y accesibles para el tratamiento de las PLDs. En ese sentido, Bañales 
JM y colaboradores propusieron evaluar el potencial terapéutico del ácido 
ursodeoxicólico (UDCA) para el tratamiento de las PLDs.  
El UDCA es un ácido biliar (bile acid, BA) endógeno ampliamente aplicado 
en clínica para el tratamiento de los trastornos colestáticos hepatobiliares. Este 
BA colerético y hepatoprotector posee importantes propiedades antioxidantes, 
antiinflamatorias, citoprotectoras y calcio-moduladoras. Dada su particular 




confinado a la circulación entero-hepática, garantizando de esta manera 
elevados niveles de biodisponibilidad hepatobiliar. Este hecho unido a la elevada 
capacidad de señalización tanto del UDCA como de sus derivados conjugados 
para estimular los niveles de iCa2+, hacen de este BA un potencial candidato para 
su aplicación en el tratamiento de las PLDs. En ese sentido, se ha observado 
que el UDCA es capaz de reducir la cistogénesis hepática y mejorar la 
sintomatología tanto en modelos experimentales (in vitro e in vivo en ratas PCK) 
como en pacientes con ADPKD avanzada, induciendo la normalización de los 
niveles de calcio intracelular en los colangiocitos poliquísticos, así como el 
descenso en la acumulación intrahepática de ácidos biliares citotóxicos y 
promitóticos. 
Por otra parte, la deacetilasa de histonas 6 (HDAC6) se encuentra 
sobreexpresada en colangiocitos poliquísticos. Este enzima se encarga de 
catalizar, entre otras, las reacciones de desacetilación de tubulina-α acetilada, 
por lo que desempeña un papel fundamental en la regulación celular de la 
homeostasis de los cilios primarios. Por tanto, y dada la importancia del cilio 
primario de los colangiocitos en la fisiopatología de las PLDs, Gradilone et al. 
decidieron evaluar el uso de inhibidores selectivos de HDAC6 para el tratamiento 
de las PLDs. En dos trabajos independientes, los autores demostraron que el 
uso de distintos inhibidores selectivos de HDAC6 administrados 
independientemente, o en combinación con la administración de análogos de 
somatostatina es capaz de inhibir significativamente la cistogénesis hepatorenal 






Los enfoques farmacológicos basados en la administración de UDCA o HDAC6is 
han proporcionado resultados muy prometedores, pero aún parciales, para el 
tratamiento de las PLDs. Por esta razón, planteamos la hipótesis de que nuevas 
entidades químicas que combinen las características de UDCA y de los HDAC6is 
en una misma estructura química podrían proporcionar un valor aditivo y/o 
sinérgico para el tratamiento de las PLDs. A ese respecto, se sabe que los 
sistemas macrocíclicos pre-organizados pueden exhibir elevadas constantes de 
unión no covalente con las cavidades externas cercanas al canal que conecta 
los sitios activos de HDAC con la superficie de estas enzimas. Por esta razón, y 
teniendo en cuenta la naturaleza policíclica del esqueleto del UDCA, 
racionalizamos que este BA endógeno podría ser un análogo 
conformacionalmente restringido adecuado para estos sistemas macrocíclicos y, 
por lo tanto, un excelente elemento estructural para el desarrollo de nuevos 
HDACis. Además, razonamos que algunas de las propiedades hepatotrópicas 
inherentes al UDCA podrían transferirse a estos nuevos HDACis, dotándolos 
propiedades hepatotrópicas, así como como de la capacidad de ser 
transportados activamente al interior de los colangiocitos poliquísticos. Es 
importante destacar que en estos nuevos compuestos no se esperaría que la 
escisión metabólica del enlace amida por la microbiota intestinal generase 
metabolitos potencialmente tóxicos, sino que diese como resultado la liberación 
de concentraciones terapéuticas de UDCA libre aumentando de esta manera la 






Con el fin de evaluar la hipótesis descrita, se propusieron los siguientes objetivos. 
1. Diseño, síntesis química y caracterización de los nuevos conjugados 
sintéticos de UDCA. 
 
2. Predicción computacional de las afinidades de unión de los UDCA-
HDAC6is hacia los dominios catalíticos 1 y 2 de HDAC6. 
 
 
3. Evaluación in vitro de la actividad inhibidora y selectividad de los UDCA-
HDAC6is en distintas HDAC individuales y colangiocitos poliquísticos. 
 
4. Estudio computacional y experimental de los factores químicos y 
estructurales que determinan la actividad y selectividad de los UDCA-
HDAC6is sobre HDAC6, y análisis de la contribución del UDCA a estos. 
 
5. Selección basada en la evidencia del UDCA-HDAC6i con mayor potencial 
traslacional para futuros estudios in vivo e in vitro. 
 
6. Evaluación in vivo del potencial terapéutico de los UDCA-HDAC6is para 
el tratamiento de las PLDs. 
 






Resultados y discusión 
Tomando como referencia la estructura cristalográfica del dominio catalítico 2 
(CD2) de la HDAC6 humana (Figura R1), llevamos a cabo el diseño y síntesis 
química de 10 nuevos derivados sintéticos de UDCA, los cuales contienen 
grupos espaciadores tanto aromáticos como alifáticos de longitud variable, así 
como grupos quelantes de Zn (II) de distinta naturaleza química (Figura R2).  
La síntesis química de las moléculas UDCA-HDAC6i comenzó con la 
reacción de acoplamiento de UDCA (1) con las aminas 2 para producir distintos 
ésteres de amida 3. La hidrólisis de estos últimos intermedios y la reacción in situ 
con hidroxilamina permitieron la obtención y caracterización de los ácidos UDCA-
hidroxámicos UDCA-HDAC6i #1, #3-6 y #10, los cuales poseen diferentes 
longitudes y características estereoelectrónicas dependiendo de la naturaleza de 
los residuos, tal como se muestra en la Figura R2 (residuos X). Estos candidatos 
incorporan grupos alquilo, fenilo, heteroarilo y quirales en sus respectivos 
componentes espaciadores. Alternativamente, la hidrólisis de los ésteres 3 
permitió la preparación de ácidos carboxílicos 4, cuyo acoplamiento posterior con 
ortofenilendiaminas 7 produjo las amidas UDCA-HDAC6i #7, #8. En otros 
ejemplos, el espaciador entre el grupo quelante y el UDCA se alargó mediante 
una secuencia adicional de acoplamiento e hidrólisis, produciendo así los ésteres 
6. La desprotección de estos ésteres metílicos y la reacción con hidroxilamina 
permitieron el aislamiento y la caracterización de los candidatos UDCA-HDAC6i 
#2, #9. En resumen, el esquema sintético que se muestra en la Figura R2 dio 
lugar a un conjunto de posibles HDACis con diferentes espaciadores y grupos 
quelantes, conteniendo todos ellos una molécula de UDCA a modo de cierre 




Seguidamente se realizó una estimación in silico mediante un modelo de 
docking de la energía de unión de estos compuestos por el dominio (CD2) de la 
HDAC6 humana (Figuras R3 y R4). Los resultados mostraron que 8 de los 10 
compuestos sintetizados mostraban cierta afinidad de unión por el sitio activo del 
enzima, siendo UDCA-HDAC6i #1, #2 y #9 los compuestos que mejores energías 
de unión mostraron (Figuras R3 y R4). Es interesante resaltar que, en los tres 
compuestos en los se obtuvieron mejores energías de unión, el esqueleto 
esteroideo del UDCA se encontraba orientado hacia la misma región de la 
superficie proteica, siendo estos tres los únicos casos en los que este se 
orientaba hacia dicha región (Figuras R3 y R4). Es por ello, que decidimos 
realizar un análisis más exhaustivo de la contribución de los distintos elementos 
estructurales a la energía de unión de cada uno de los compuestos (Figura R5). 
En dicho análisis, observamos que en los tres casos anteriormente mencionados 
las interacciones ejercidas por el UDCA suponían alrededor de un tercio de la 
energía total de unión, siendo estas principalmente interacciones de van der 
Waals y enlaces de hidrogeno (Tabla R1). 
A continuación, llevamos a cabo experimentos de docking sobre un 
modelo de homología generado a partir de la estructura cristalográfica del 
dominio catalítico 1 (CD1) de HDAC6 de pez cebra (Figura R6). En dichos 
experimentos se pudo observar que mientras que UDCA-HDAC6i #2 y #9 
mantenían un alto grado de afinidad por CD1, la afinidad de UDCA-HDAC6i #1 
por CD1 era menor que la mostrada por CD2 (Tabla R2). 
Una vez confirmada mediante experimentos de immunoblot la 
sobreexpresión de HDAC6 en colangiocitos poliquísticos (Figura R7), se propuso 




Para ello, se incubaron cultivos celulares de colangiocitos humanos poliquísticos 
con los distintos derivados sintéticos de UDCA. A continuación, se analizaron los 
niveles de acetilación de tubulina-α como medida de la inhibición frente a 
HDAC6, así como los niveles de acetilación de la lisina 9 de la histona 3 (H3K9) 
como medida de la inhibición de HDACs nucleares (Figura R8). En estos 
experimentos se observó que los compuestos UDCA-HDAC6i #1, #2, #6 y #9 
inhibieron selectivamente HDAC6, induciendo un aumento substancial en la 
acetilación de tubulina-α, sin modificar de forma aparente los niveles de 
acetilación de H3K9 (Figura R8). Paralelamente, se observó que UDCA-HDAC6i 
#8 aumentó los niveles de acetilación de H3K9, siendo este un potencial inhibidor 
selectivo de HDACs nucleares (Figura R8). Por último, la comparativa de estos 
resultados con los resultados previamente obtenidos en los estudios de docking 
sobre el CD2 de HDAC6 mostró un elevado índice de correlación entre ambos 
parámetros, confirmando de esta manera la precisión del modelo computacional 
(Figura R9), cuyas capacidades predictivas pueden ser utilizadas en futuros 
desarrollos. 
Seguidamente, se decidió analizar en enzimas purificadas la capacidad 
inhibitoria de los 5 compuestos que mejores resultados habían mostrado en 
cultivos celulares de colangiocitos poliquísticos (Figura R10). En este 
experimento se confirmaron los elevados índices de actividad y selectividad de 
UDCA-HDAC6i #1, #2, #6 y #9 sobre HDAC6, siendo especialmente relevantes 
los resultados obtenidos para UDCA-HDAC6i #1, #2, y #9 (Figura R10). Así pues, 
estos experimentos revelaron el elevado índice de actividad y selectividad de 
UDCA-HDAC6i #8 por HDAC1 (Figura R10). Además, a pesar de que el UDCA 




que el valor de IC50 de UDCA-HDAC6i #1 para HDAC6 era un orden de 
magnitud menor que para el grupo quelante aislado para ese mismo enzima 
(Figura R10 y Tabla R3). Este resultado es especialmente relevante, ya que la 
única diferencia estructural entre estos dos compuestos es la presencia de una 
molécula de UDCA en el primero, lo cual confirma la importancia de la 
contribución del UDCA al efecto inhibitorio de los UDCA-HDAC6is propuesta a 
partir de las observaciones realizadas en los experimentos computacionales 
(Tabla R1). 
Análisis exhaustivos de las interacciones individuales más relevantes 
observadas en los experimentos computacionales sobre el CD2 de la HDAC6 
humana, así como comparativas estructurales entre los compuestos ensayados 
en HDAC purificadas revelaron información importante (Tabla R4 y Figura R11). 
Por un lado, estos estudios pusieron de manifiesto la importancia del ácido 
hidroxámico para la actividad inhibitoria de los UDCA-HDAC6is sobre HDAC6. 
Por otra parte, indicaron el papel fundamental de los espaciadores 1, 4-fenileno 
en la determinación de la selectividad de estos compuestos mediante la 
orientación del esqueleto hidrocarbonado del UDCA hacia una región concreta 
de la superficie enzimática. De acuerdo con esto, el alineamiento mediante 
métodos computacionales de las estructuras cristalográficas de los dominios 
catalíticos de las HDAC1, 2, 3, 4, 7, 8 humanas, así como la HDAC10 de pez 
cebra, con nuestro modelo de docking en HDAC6 CD2, reveló información crucial 
sobre la importancia de la orientación del UDCA para la selectividad inhibitoria 
(Figuras R12 y R13). En dicho análisis se observó que la cavidad superficial 
preferentemente ocupada en HDAC6 por el UDCA presente en los 3 compuestos 




mientras que las cavidades superficiales ocupadas por el UDCA en el resto de 
compuestos se encontraban prácticamente intactas en todas las HDACs 
analizadas (Figuras R12 y R13). Seguidamente seleccionamos UDCA-HDAC6i 
#1 como el candidato con mayor potencial traslacional basándonos en su 
potencia y selectividad inhibitorias, así como en sus propiedades 
farmacocinéticas y su bajo coste sintético (Figuras R2 y R10 y Tabla R5). 
Con el objetivo de evaluar el potencial terapéutico de UDCA-HDAC6i #1 
para el tratamiento de las PLDs, se llevó a cabo un ensayo in vivo de tratamiento 
crónico en un modelo animal de poliquistosis hepatorenal (ratas PCK). En dicho 
ensayo se trataron ratas PCK macho de 8 semanas de edad con una dosis oral 
diaria de 15 mg/kg día durante 5 meses. El tratamiento crónico de estos animales 
produjo una reducción significativa tanto de la hepatomegalia como de la 
nefromegalia asociadas al desarrollo de la enfermedad (Figuras R15 y R26). 
Además, se observó un aumento significativo en los niveles séricos de albúmina, 
así como un descenso en la concentración de urea en sangre, indicando sendas 
mejoras de las funciones hepática y renal respectivamente (Figuras R15 y R16). 
En cuanto a la farmacocinética, se observó una acumulación preferencial del 
compuesto en bilis en comparación con sangre portal y sistémica, así como tejido 
hepático (Figura R17). Además, se observó un aumento significativo en los 
niveles de acetilación de tubulina-α tanto en tejido hepático como renal, 
confirmando de esta manera un efecto farmacológico directo del compuesto 
administrado sobre estos tejidos (Figura R18). 
En cuanto a la concentración de los distintos BAs, se observaron ciertas 
diferencias entre los animales tratados y no tratados en los niveles relativos de 




los incrementos significativos observados en las concentraciones de UDCA en 
bilis, hígado, sangre portal y sangre sistémica de los animales tratados, lo cual 
parecería indicar un aumento importante de la biodisponibilidad del UDCA 
originado a partir del metabolismo del UDCA-HDAC6i #1 administrado (Figura 
R20). 
Los análisis histológicos revelaron que el tratamiento crónico con UDCA-
HDAC6i #1 produjo un descenso significativo de la cistogénesis hepática (Figura 
R21). Además, a nivel celular el aumento en los niveles de acetilación de 
tubulina-α se vio traducido en una elongación significativa del cilio primario de 
los colangiocitos poliquísticos, mientras que no tuvo efecto aparente sobre la 
longitud del cilio primario de los colangiocitos normales (Figura R22). 
La incubación con UDCA-HDAC6i #1 de estructuras quísticas 
(colangioides) cultivadas en 3D en matrices de colágeno tipo I, reveló un efecto 
antiproliferativo significativo del compuesto sobre dichas estructuras (Figura 
R23). A nivel molecular, se observó que la incubación de colangiocitos 
poliquísticos cultivados en monocapa con UDCA-HDAC6i #1 producía un 
descenso en los niveles de fosforilación de ERK1/2 (Figura R24). Además, se 
analizó este efecto antiproliferativo mediante ensayos de citometria de flujo con 
colangiocitos poliquísticos sometidos a distintos tratamientos. En dichos 
ensayos, se pudo observar una clara relación de dosis-dependencia en el efecto 
antiproliferativo de UDCA-HDAC6i #1 (Figura R24). Particularmente interesante 
resultó el hecho de que la incubación con UDCA-HDAC6i #1 produjo un efecto 
anti-proliferativo mucho mayor que la incubación combinada con sus dos 
componentes estructurales farmacológicamente activos (UDCA + grupo 




Por último, se estudiaron los posibles mecanismos de transporte celular 
activo de estos derivados sintéticos de UDCA (Figura R25). En dichos 
experimentos se observó que UDCA-HDAC6i #1 era activamente transportado 
tanto por el transportador de ácidos biliares NTCP, como por los transportadores 
de cationes orgánicos OCT1 y OCT3, encontrándose estos últimos 
significativamente sobre-expresados en colangiocitos poliquísticos con respecto 


















I. Cuatro de las entidades moleculares UDCA-HDAC6i sintetizadas poseen 
una capacidad inhibitoria sobre HDAC6 potente y altamente selectiva, 
mientras que un quinto compuesto sintetizado exhibe actividad inhibitoria 
altamente selectiva frente a las HDAC nucleares. 
II. El UDCA contribuye activamente a la actividad inhibitoria sobre HDAC6 
de los compuestos UDCA-HDAC6is al establecer interacciones de van der 
Waals y enlaces de hidrógeno con residuos de las cavidades externas de 
los dominios catalíticos de dicho enzima. Esta contribución puede 
representar hasta un tercio de la energía de unión total del compuesto. 
III. La pre-organización y la orientación preferencial del UDCA hacia una 
región particular de la superficie de HDAC6 CD2 es crítica para la 
selectividad y la potencia inhibitoria de los compuestos UDCA-HDAC6i. 
IV. UDCA-HDAC6i #1 es el candidato con mayor potencial traslacional debido 
a su potencia y selectividad inhibitorias sobre HDAC6, así como sus 
propiedades farmacocinéticas favorables y menor coste sintético. 
V. Tras la administración oral, UDCA-HDAC6i #1, este se acumula 
preferentemente en bilis, lo que indica una buena capacidad de 
vectorización hacia el sistema hepatobiliar. 
VI. El tratamiento crónico de ratas PCK con UDCA-HDAC6i #1 redujo su 
hepato- y nefromegalia, disminuyó su cistogénesis hepática, y mejoró las 
funciones hepáticas y renales en estos animales. Además, el aumento de 
los niveles de α-tubulina acetilada en el hígado y los riñones de los 





VII. El tratamiento oral crónico con UDCA-HDAC6i #1 produjo una 
modificación significativa en la proporción relativa de algunos BAs en 
ratas PCK, siendo particularmente relevante el aumento en la 
concentración de UDCA libre observado en el hígado, la bilis y el suero 
de los animales tratados. 
VIII. Los cilios primarios de los colangiocitos humanos poliquísticos son 
significativamente más cortos que los de los colangiocitos humanos 
normales. La incubación de colangiocitos humanos poliquísticos con 
UDCA-HDAC6i #1 aumentó los niveles de α-tubulina acetilada de una 
manera dosis-dependiente y produjo una elongación significativa de los 
cilios primarios de estas células. Por el contrario, estos efectos no se 
observaron en los colangiocitos humanos normales. 
IX. La incubación de colangiocitos poliquísticos con UDCA-HDAC6i #1 inhibió 
la hiperproliferación de estas células en cultivos 2D y 3D. Este efecto 
antiproliferativo fue superior al ejercido por el tratamiento combinado con 
sus componentes farmacológicamente activos. 
X. La incubación de colangiocitos poliquísticos con UDCA-HDAC6i #1 redujo 
la fosforilación de ERK1/2, lo que permite profundizar en la naturaleza de 
los mecanismos moleculares implicados en este efecto antiproliferativo. 
XI. UDCA-HDAC6i# 1 se transporta activamente a través del transportador 
de ácidos biliares NTCP y de los transportadores de cationes orgánicos 






En conjunto, estos hallazgos abren la posibilidad de una nueva vía terapéutica 
para el tratamiento de las PLDs y pueden proporcionar datos útiles para futuros 
desarrollos farmacológicos, ya sea en el campo de la actividad y selectividad de 
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